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Summary 
Short stature due to progressive growth failure in mucopolysaccharidosis (MPS) does not 
respond to current treatment. The mechanism behind impaired bone growth in MPS is poorly 
understood but is crucial to the development of improved strategies to alter bone growth.  
Bone length was measured in 5 mouse models of MPS to determine the best model for further 
analysis. The severe MPS VII mouse model (Gusmps/mps strain) displayed the greatest reduction 
in bone length and was chosen as the model for studying bone shortening in MPS. Bone 
formation was delayed in both the primary and secondary ossification centres in MPS VII mice. 
The growth plate was thickened with enlarged chondrocytes in the resting (RZ) and 
hypertrophic zones (HZ) but there was a reduced number of chondrocytes in the proliferative 
zone (PZ) and HZ. 
Chondrocytes progress through the cell cycle to proliferate and withdraw from the cell cycle 
to differentiate. Immunohistochemical analysis of cell cycle regulators in the MPS VII growth 
plate revealed that fewer chondrocytes progressed to mitotic division for proliferation. Fewer 
HZ chondrocytes progressed to cell cycle withdrawal for terminal differentiation in MPS VII 
growth plate. Thus, MPS VII chondrocytes while committed to the cell cycle were unable to 
progress normally through the different stages.  
Circulating GH, T3 and IHH levels in MPS VII mice were not significantly different from 
normal. However, IGF1 production in MPS VII mice was reduced both in the circulation and 
in primary hepatocytes culture, suggesting an impaired GH/IGF1 signaling pathway in MPS 
VII mice, which may limit the proliferation of chondrocytes in the growth plate. This 
dysfunction of GH/IGF1 signaling was not caused by a deficiency of the hepatic growth 
hormone receptor but was associated with a reduction in tyrosine phosphorylation of STAT5 
in MPS VII liver. Responsiveness of MPS VII chondrocytes to GH was decreased and local 
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growth plate expression of GHR was reduced, indicating that GHR deficiency may cause the 
reduced proliferation in MPS VII growth plate. 
Proliferation and differentiation of chondrocytes are also regulated by locally expressed factors 
such as IHH, PTHrP and IGF1. Reduced IHH protein level was observed in MPS VII growth 
plate and in chondrocyte culture, suggesting a potential relationship between IHH and the 
reduced number of chondrocytes in the PZ of MPS VII growth plate. Persistent expression of 
Pthrpr and Sox9 and elevated IGF1 secretion by chondrocytes indicated relationships between 
altered PTHrP and IGF1 signalling pathways and the delayed hypertrophic transition of 
chondrocytes in the MPS VII growth plate.  
This thesis highlights that the bone phenotype of MPS is established before birth and suggests 
that the decreased numbers of chondrocytes in the PZ and HZ of MPS VII growth plate are the 
results of disruptions in the pace of cell cycle progression. Decreased GHR level would also 
contribute to reduction of chondrocyte proliferation. Although a decrease in circulating IGF1 
level and a decrease in IHH expression in the growth plate was observed, a direct relationship 
between these observations and short stature cannot be established.  
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1.1 Mucopolysaccharidosis 
The mucopolysaccharidosis (MPS) are a group of lysosomal storage disorders that result 
from deficiencies in enzymes catalysing the degradation of glycosaminoglycans (GAGs). 
Long, unbranched GAG chains are located primarily in the extracellular matrix (ECM) and 
pericellular matrix and are essential in building bones, cartilage, skin, tendons and many 
other tissues in the body (Alberts et al. 2008). In the course of normal life, GAGs are 
continuously renewed and such involves breaking down GAGs by a series of enzymes 
working in sequence.  
The accumulation of undegraded or partially degraded GAGs in MPS cells leads to 
dysfunction in multiple tissues and organs. Eleven known MPS enzyme deficiencies have 
been characterised (Table 2.1) (Muenzer 2011; Neufeld & Muenzer 2001). All MPS are 
inherited in an autosomal recessive manner except for MPS II, which is an X-linked 
recessive disease. MPS patients display various symptoms depending on MPS type and 
severity, but patients commonly present with hepatosplenomegaly, corneal clouding, upper 
airway disease, cardiac defects, central nervous system deterioration, skeletal dysplasia, 
decreased joint mobility, short stature and abnormal facies (Neufeld & Muenzer 2001).  
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Table 2.1 Classifications of MPS.  
Disorder Enzyme deficiency GAG affected Genetic inheritance 
MPS I α-L-iduronidase DS, HS Autosomal recessive 
MPS II Iduronate-2-sulphatase DS, HS X-linked recessive 
MPS III 
A: heparan N-sulphatase 
HS 
Autosomal recessive 
B: α-N-acetylglucosaminidase Autosomal recessive 







A: galactose 6-sulphatase A: KS, CS Autosomal recessive 
B: β-galactosidase B: KS Autosomal recessive 
MPS VI Arylsulphatase B DS, CS Autosomal recessive 
MPS VII β-Glucuronidase DS, HS,CS Autosomal recessive 
MPS IX Hyaluronidase HA Autosomal recessive 
Note: DS=dermatan sulphate; HS=heparan sulphate; KS=keratan sulphate; 
CS=chondroitin sulphate; HA=hyaluronan 
Adapted from (Muenzer 2011) 
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1.2 Short stature 
Short stature is observed in MPS I, MPS II, MPS IV, MPS VI, and MPS VII patients 
(Melbouci et al. 2018; Neufeld & Muenzer 2001). Growth and final height are significantly 
reduced (Table 2.2; (Neufeld & Muenzer 2001), with the final height -3 to -6 standard 
deviations below that of normal children of the same age and gender (Polgreen & Miller 
2010). While affected children may be at a normal length at birth, growth failure becomes 
progressively worse with age. Growth velocity of severely affected children declines 
significantly after 1 year of age, and their growth effectively stops around the age of 2-6 
years (Kubaski et al. 2016; Montano et al. 2016; Montaño et al. 2008; Patel, Suzuki, Maeda, 
et al. 2014; Quartel et al. 2015; Rozdzynska-Swiatkowska et al. 2015). Such extreme short 
stature has a significant, negative influence on daily life, education and career choices of 
affected patients (Polgreen & Miller 2010; Ross et al. 2004; Zimet et al. 1997). Short stature 
can be attributed to a combination of a primary failure of growth plate transition into bone, 
joint contractures, skeletal deformities including spine curvatures, genu valgum and hip 
dysplasia, as well as endocrine and nutrient deficiencies (Field et al. 1994; Polgreen et al. 
2008). The role of each mechanism in affecting MPS bone growth is still poorly understood. 
This thesis describes a series of experiments aimed at elucidating the cause of poor bone 
growth using MPS murine models.  
  
5 | P a g e  
 
Table 2.2 Final height of MPS patients 
MPS type Final height (cm) 
MPS I ~110 (Neufeld & Meunzer 2001) 
MPS II ~151 (Rozdzynska et al. 2011) 
MPS IVA 113 (F)/122 (M) (Montaño et al. 2008) 
MPS VI 110-140 (Neufeld & Meunzer 2001) 
MPS VII 96~159 (Montano et al. 2016; Sly et al. 1973) 
MPS IX 
145.5 (F, 14yr) (Natowicz et al. 1996) 
161 (F)/177 (M) (Imundo et al. 2011) 
Average normal adult female (F) and male (M) height is 164.5cm and 178.4cm, respectively 
(Australian Bureanu of Statistics, 1995).  
 
1.3 MPS therapies 
Treatments, including hematopoietic cell transplantation (HCT) and enzyme replacement 
(ERT), are currently available for select patients with MPS I, II, IVA, VI and VII (Chinen 
et al. 2014; Decker et al. 2010; Fox et al. 2015; Furujo, Kosuga & Okuyama 2017; Harmatz 
et al. 2017; Herskhovitz et al. 1999; Hobbs et al. 1981; Jones, SA et al. 2013; Kakkis et al. 
2001; McGill et al. 2010; Muenzer et al. 2006; Patel, Suzuki, Tanaka, et al. 2014; Polgreen 
et al. 2009; Polgreen et al. 2008; Sands & Birkenmeier 1993; Schulze-Frenking et al. 2011; 
Sifuentes et al. 2007; Sohn et al. 2013; Vellodi et al. 1997; Yamada et al. 1998). HCT (either 
bone marrow or stem cell transplantation), and ERT have significantly diminished some 
symptoms of MPS including respiratory diseases, cardiovascular dysfunction, joint 
mobility, liver and spleen pathology, and coarse facial features (Cox-Brinkman et al. 2006; 
Herskhovitz et al. 1999; McGill et al. 2010). However, not all symptoms respond equally to 
these therapies. Musculoskeletal and joint abnormalities seem to have no or short-lived 
response to the current treatments (Arora et al. 2007; Chinen et al. 2014; Field et al. 1994; 
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Furujo, Kosuga & Okuyama 2017; Harmatz et al. 2017; Herskhovitz et al. 1999; Horovitz 
et al. 2013; Polgreen et al. 2008; Tylki-Szymanska et al. 2010; Zuber et al. 2014). Both 
therapies require early and accurate diagnosis to obtain the best outcome due to the 
irreversible nature of some symptoms (Prasad & Kurtzberg 2010).  
A small improvement in growth was observed in children with MPS I post-HCT, however, 
these patients were still significantly shorter than normal (Gardner et al. 2011). In a 15 years 
follow-up study, the linear growth of MPS I patients after HCT at 20 months of age 
continued for some years, but gradually decreased with time (Vellodi et al. 1997). 
Furthermore, the conditioning regimen used in HCT has itself been associated with adverse 
effect on growth due to one or more of the following reasons; growth hormone (GH) 
deficiencies, abnormal gonadal and thyroid functions, and damage to the epiphyseal growth 
plate, pituitary gland and hypothalamus by radiation and chemotherapy (Brennan & Shalet 
2002; Frisk et al. 2004; Giorgiani et al. 1995; Huma et al. 1995; Legault & Bonny 1999; 
Polgreen et al. 2008; Ranke et al. 2005; Shalitin et al. 2006). For example, the prevalence 
of growth failure in children with MPS I after HCT who had no total body irradiation (TBI) 
exposure is 32% less than those who had TBI exposure. Therefore, HCT as treatment for 
skeletal defects of MPS is of limited efficacy. 
While some studies report a continuing decline in height such that MPS children on ERT 
regimens are not different to untreated patients (Arora et al. 2007; Tylki-Szymanska et al. 
2010), other studies report an increase in growth velocity after ERT (Decker et al. 2010; 
Jones, SA et al. 2013; Kakkis et al. 2001; Pineda et al. 2016; Schulze-Frenking et al. 2011; 
Sifuentes et al. 2007). However, in no case did the height of treated MPS patients 
approached normal values (Fox et al. 2015; Furujo, Kosuga & Okuyama 2017; Harmatz et 
al. 2017; Horovitz et al. 2013; Sohn et al. 2012; Zuber et al. 2014). Response to ERT was 
greatest in prepubertal children (27% improvement of growth velocity) as compared to 
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pubertal children (0.5% improvement) (Sifuentes et al. 2007). Therefore, the age of MPS 
children at which the ERT starts thus defines the capacity for further growth. As age is a 
crucial factor in the response to the therapy, this may explain the conflicting results observed 
in different studies. 
Studies in animal models also show mixed results. Improvement of bone length was not 
observed in MPS animals after HCT or ERT (Birkenmeier et al. 1991; Byers et al. 1997; 
Crawley et al. 1997; Pievani et al. 2014; Rowan et al. 2012; Sands et al. 1993; Sands et al. 
1994; Vogler et al. 1996). A single study that used a chemically modified form of GUS for 
prolonged circulation in MPS VII mice showed improvements in tibia length (Rowan et al. 
2012). However, the efficacy of this treatment with modified form of GUS on MPS patient 
has not been reported.  
Trials using gene therapy (GT) in MPS affected animals showed improvement of bone 
length when normal or sub-normal level of circulating enzyme are achieved (Daly et al. 
2001; Elliger et al. 2002; Mango et al. 2004). A level of 50% of normal circulating enzyme 
is suggested as the minimum level to rescue the defects of longitudinal bone growth 
(Cotugno et al. 2010). However, not all bones respond to treatment. The radius and tibia of 
MPS VII mice treated with gene therapy were longer than those of untreated MPS VII mice 
(Donsante et al. 2007), while femur length was not different to untreated mice(Daly et al. 
2001; Derrick-Roberts et al. 2014; Elliger et al. 2002; Macsai et al. 2012). Thus, the 
efficiency of gene therapy on bone correction is dependent on the differences in growth rate. 
Overall, applications of BMT, ERT and GT have limited efficacy for improving bone 
growth in MPS animal models. To maximize the effectiveness and to translate beneficial 
results of these approaches from animals to human patients, a better understanding of the 
pathology of growth retardation in MPS is required. 
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Figure 1.1 Histology of a long bone and its growth plate. Endochondral ossification of 
long bone during childhood (Left, modified from the Primer on the Metabolic Bone 
Diseases and Disorders of Mineral Metabolism, Chapter 1, Figure 9 (Yang, Yingzi 2009). 
The growth plate is located at each end of a long bone. Alcian blue stained mouse proximal 
tibial growth plate (right, derived from Matrix Biology Unit, SA Pathology), showing the 
resting, proliferating and hypertrophic zones. S-secondary ossification centre. 
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1.4 Mechanism of longitudinal bone growth  
While the mechanism behind poor bone growth in MPS is poorly understood, the 
mechanism of normal bone growth is better characterised. Bones continually change in size 
and shape, from foetal development until maturity. The growth plate, a mesoderm-derived 
cartilage template, is the tissue responsible for bone growth via endochondral ossification 
(EO), whereby rapidly growing cartilage is replaced by bone. 
1.4.1 Growth plate and endochondral ossification 
During bone formation, the primary ossification centre (POC) is formed at the middle of 
cartilage template, and the secondary ossification centre (SOC) is formed at each end of the 
developing bone, leaving the cartilaginous growth plates between the POC and SOC (Figure 
1.1) (Yang, Yingzi 2009). Eventually, the growth plates vanish as the ossification centres 
meet at maturity and bone growth ceases (Mackie et al. 2008).  
During formation of the POC, chondrocytes differentiate to hypertrophic chondrocytes from 
the middle of diaphysis in mice. Hypertrophic chondrocytes secrete ECM and enzymes 
including matrix metalloproteinase (MMP) 13 and MMP 14 that degrade Type II collagen 
and aggrecan (Holmbeck et al. 1999; Inada et al. 2004; Mitchell et al. 1996). The 
surrounding ECM is then mineralised through the deposition of hydroxyapatite that consists 
of calcium and phosphate (Gerber et al. 1999; Hunziker 1994). Vascular endothelial growth 
factors (VEGF) are also expressed by hypertrophic chondrocytes, which allows rapid 
invasion of vascular endothelial cells from the bone collar through pre-existing cartilage 
canals, into the calcified matrix in the future POC site (Burkus, Ganey & Ogden 1993; 
Carlevaro, M.F. et al. 2000; Maes, C. et al. 2004). Blood vessels are also formed for 
transporting of hematopoietic and osteogenic cells for marrow and bone deposition (Maes, 
Christa & Kronenberg 2016). MMP 9 expressed by osteoclasts and endothelial cells 
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degrades cartilaginous matrix and releases VEGF from ECM (Gerber et al. 1999; Vu et al. 
1998). The latter triggers the sprouting of new vessels at metaphysis, which is also 
facilitated by fibroblast growth factors (FGFs) and connective tissue growth factors 
(CTGFs) (Baron et al. 1994; Ivkovic et al. 2003; Nishida et al. 2009; Seghezzi et al. 1998; 
Shimo, T. et al. 1998). 
Chondrocytes in the growth plate arrange themselves into morphologically distinct zones, 
which reflect their different lifespan (Figure 1.1). Chondrocytes in the resting zone (RZ) are 
irregularly arranged and rarely divide, and occupy the region nearest to the epiphysis. RZ 
chondrocytes are believed to replenish the adjacent proliferative zone (PZ) (Abad et al. 
2002). Chondrocytes undergo division in the PZ, appearing as flattened cells which are 
arranged in columns parallel to the long axis of the bone (Abad et al. 2002). After 
replication, the cells gradually enter the hypertrophic stage, enlarging their volume about 6 
to 10-fold, increasing alkaline phosphatase enzyme activity, and secreting type X collagen 
(Cooper et al. 2013; Farnum et al. 2002). Hypertrophic chondrocytes eventually die either 
through apoptosis or autophagic cell death (Ahmed et al. 2007; Shapiro et al. 2005). 
Removal of the transverse septa of the cartilage ECM allows invasion of the ossification 
front, including blood vessels, osteoclasts, and bone marrow cells and osteoblast precursors. 
Osteoclasts erode the mineralised ECM, and osteoblasts continuously deposit bone matrix 
(Hall & Miyake 1995).  
Vascularization and formation of the SOC are slightly different to those of the POC. Shortly 
after birth, hypertrophic chondrocytes in the middle of the epiphysis secret MMP14, which 
clears a path for the formation of cartilage canals that contains blood vessel and perivascular 
cells. MMP13 and A Disintegrin and Metalloproteinase with Thrombospondin Motifs 
(ADAMTS) 5 (Hurskainen et al. 1999; Makihira et al. 2003; Stanton et al. 2005) expressed 
by the hypertrophic chondrocytes degrades both type II collagen and aggrecan. 
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Hypertrophic chondrocytes in the future SOC site forms a hypoxic and avascular tissue. 
Secretion of VEGFs by chondrocytes surrounding cartilage canals in the hypoxic site is 
induced by hypoxia inducible factor (HIF) (Lin, X 2004; Maes, C. 2017), stimulating blood 
vessel invasion in the epiphysis of long bones (Allerstorfer et al. 2010). Transportation of 
osteoclasts, osteoblasts and hematopoietic cells through blood vessels thus initiates 
formation of the SOC in the epiphysis (Maes, Christa & Kronenberg 2016).  
Thus, the key regulatory points in EO are:  
(i) entry into the cell cycle (proliferation);  
(ii) exit from the cell cycle and initiation of hypertrophy;  
(iii) blood vessel invasion from the metaphysis of long bones 
The behaviour of chondrocytes during EO is highly regulated by a group of endocrine and 
paracrine factors and components of the cartilage ECM. 
1.4.2 Regulation of endochondral ossification 
Sequential proliferation, ECM secretion and hypertrophy of growth plate chondrocytes are 
required for proper skeletogenesis, and are regulated by a number of systemic factors, 
including GH, thyroid hormone, glucocorticoids, estrogen and testosterone (Clarke, BL & 
Khosla 2009; Fernandez-Cancio et al. 2008; Goldring, Tsuchimochi & Ijiri 2006; van der 
Eerden, Karperien & Wit 2003), paracrine/autocrine factors such as insulin like growth 
factors (IGF), indian hedgehog (IHH), and parathyroid hormone-related peptide (PTHrP), 
their downstream transcription factors, as well as by GAGs and other components of ECM 
(Figure 1.2). 
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Figure 1.2 Regulation of growth plate chondrocyte proliferation and hypertrophy 
during EO. Systemic factors (red), paracrine/autocrine factors (blue), transcription factors 
(green) and other factors (black) are involved. Arrows indicate stimulatory pathways, and 
crossed lines indicate inhibitory pathways. Based on Mackie et al. (2008). GH, growth 
hormone. T3, triiodothyronine. IGF1, insulin growth factor 1. PTHrP, parathyroid hormone 
related peptide. BMPs, bone morphogenetic proteins. Ihh, indian hedgehog. Gli3, glioma-
associated oncogene homologue. Wnt, wingless-type mouse mammary tumor virus 
integration site. Sox9, SRY-Box 9. Runx2, Runt-related transcription factor 2. FGF, 
Fibroblast growth factor. FGFR, fibroblast growth factor receptor. MMP, Matrix 






















Matrix degradation and 
vascularization
13 | P a g e  
 
1.4.2.1 Systemic factors 
1.4.2.1.1 1. Growth hormone and liver-derived IGF1 
GH is secreted by the anterior pituitary gland (Veldhuis & Bowers 2003) in a basal and a 
pulsatile pattern under the regulation of GH-releasing hormone (GHRH) and somatostatin 
from the hypothalamus. GH is released into the bloodstream and primarily acts on the liver 
where it stimulates the production of endocrine form of IGF1(Butler & Le Roith 2001). It 
is also an important stimulator of chondrocyte proliferation in the growth plate where it 
induces resting cells to enter the proliferative cycle (Baker et al. 1993; Hunziker, Wagner 
& Zapf 1994; Isaksson, Jansson & Gause 1982). GH functions through the growth hormone 
receptor (GHR), which is expressed systemically by hepatocytes and locally by 
chondrocytes in all layers of the growth plate (Gevers et al. 2002; Ram et al. 1996). Pituitary 
secretion of GH is both age- and sex-dependent. The level of free GH is normally high after 
birth and decreases slightly until puberty. At puberty, it reaches a peak and then 
continuously decreases with age during adulthood. Females normally have a higher level of 
GH than males. Excess GH due to pituitary adenomas results in gigantism (Nilsson, O et al. 
2005), while a shortage of GH due to mutations in GHRs or defects in GH signalling 
pathways causes impaired postnatal growth (Wit, Kamp & Rikken 1996).  
Acceleration of longitudinal growth in GH-injected tibial growth plates of rats was observed 
when compared to saline-injected growth plates, supporting the theory that GH directly 
stimulates chondrocyte proliferation (Isaksson, Jansson & Gause 1982). However, the 
effects of GH on chondrocytes in vitro reported by various research groups are conflicting. 
In some cases, no response was observed with GH alone (Jones, KL, Villela & Lewis 1986; 
Trippel et al. 1989), while in combination with IGF1, GH stimulated DNA and matrix 
synthesis (Smith, Kuniyoshi & Talamantes 1989). It is not clear what causes the 
discrepancy, but variations in experimental conditions, including the initial cell density, 
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time of cell culture and the existence of serum in the medium may all contribute (Isaksson 
et al. 1990). 
IGF1 is the primary mediator of GH. GH binds to the dimerized transmembrane GHR, 
triggering the activation of Janus kinase 2 / signal transducer and activator of transcription 
5 (JAK2/STAT5) signalling cascade (Figure1.3) (Piwien-Pilipuk, Huo & Schwartz 2002; 
Teglund et al. 1998). Upon phosphorylation and dimerization, STAT5 translocates to the 
nucleus and binds onto the promoter of the target gene induces hepatic IGF1 synthesis 
(Rotwein 2012; Woelfle, Billiard & Rotwein 2003), as well as IGF binding protein 
(IGFBP3) and the acid labile subunit (IGFALS) (Baxter, Martin & Beniac 1989). These 
proteins form a protective ternary complex, which prolongs the half-life of IGF1 in the 
circulation and regulates the bioavailability of IGF1 to bones. Liver-derived IGF1 
contributes 75% of IGF1 in the circulating pool (Sjogren et al. 1999; Yakar et al. 1999). 
IGF1 is then released to bone and bound by bone/cartilage-derived IGFR1 to regulate EO. 
While bone growth is mainly regulated by GH-independent IGF2 before birth (Baker et al. 
1993; DeChiara, Efstratiadis & Robertsen 1990), IGF1 stimulate linear bone growth during 
postnatal life (Schlegel et al. 2010; Yakar et al. 2002). Yakar et al. (2002) reported that 
reduction in IGF1 levels leads to decreased linear bone growth, while circulating IGF1 
treatment was able to resuce longitudinal bone growth in both human and mice with GHR 
mutations (Guevara-Aguirre et al. 1997; Sims et al. 2000). IGFR1 is an essential mediator 
of IGF1, and mice with a deficiency of IGFR1 display more severe growth retardation than 
those without IGF1 itself (Baker et al. 1993). 
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Figure 1.3 GH mediated IGF1 production in liver. Binding of growth hormone (GH) 
triggers dimerization of the cell surface growth hormone receptor (GHR), which activates 
Janus kinase 2 (JAK2) through phosphorylation. Activated JAK2 lead to phosphorylation 
of the GHR and subsequently cytoplasmic transcription factors including signal transducer 
and activator of transcription 5 (STAT5). Phosphorylated STATs dimerize and translocate 
to the nucleus, where they bind onto the promoter of target genes (insulin like growth factor 
1 (Igf1), IGF binding protein 3 (Igfbp3) and IGF acid labile subunit (Igfals)). Secreted 
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1.4.2.1.2 Thyroid hormone 
Thyroid hormone is important in supporting cell hypertrophy at the expense of proliferation. 
In humans, hyperthyroidism accelerates longitudinal bone growth and EO, while 
hypothyroidism slows these processes by attenuating the growth plate and impairing 
chondrocyte hypertrophy (Buckler, Willgerodt & Keller 1986; Leger & Czernichow 1989). 
Thyroid hormone level is the highest in the first month after birth, and subsequently 
decreases with age before adulthood (Kapelari et al. 2008).  
Two primary thyroid hormones, triiodothyronine (T3) and thyroxine (T4) are produced by 
the thyroid gland. T4 is the precursor of T3 and must be converted to T3 to function 
(Leonard & Kohrle 1996). T3 stimulates morphological hypertrophy, expression of collagen 
type X as well as alkaline phosphatase activity, and diminishes proliferation in vitro 
(Ballock & Reddi 1994; Burch & Lebovitz 1982; Robson et al. 2000). Two thyroid hormone 
receptors, TR-α and TR-β, are expressed in growth plate chondrocytes (Ballock et al. 1999). 
TR-α is the major mediator of T3 action on mouse growth plate cartilage (Forrest et al. 
1996; Gauthier et al. 1999; Kaneshige et al. 2001), while both receptors may be important 
in humans (Takeda et al. 1992). In addition, GHR and IGF type I receptor (IGFR1) are T3-
responsive, indicating that T3 may also act through the GH/IGF1 axis. (O'Shea et al. 2005).  
1.4.2.2 Locally secreted factors & transcription factors 
1.4.2.2.1 IGF1 
Local secretion of IGF1 in the growth plate is also promoted by GH (Isgaard et al. 1988; 
Nilsson, A et al. 1990). It is produced by RZ and PZ chondrocytes and acts as an 
autocrine/paracrine factor to promote growth plate chondrogenesis (Isgaard et al. 1988; 
Parker et al. 2007; Schlegel et al. 2010). Cartilage-specific IGF1 (Wang, Y et al. 2006) and 
IGFR1 (Wang, Y et al. 2011) null mice exhibit apparent growth retardation. 
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1.4.2.2.2 IHH & GLI3 
IHH is secreted by pre-hypertrophic (pre-HZ) and early hypertrophic chondrocytes and it 
regulates chondrocyte proliferation and hypertrophy (Koyama et al. 1996; Maeda et al. 
2007; St-Jacques, Hammerschmidt & McMahon 1999; Vortkamp et al. 1996). Ihh-null mice 
display reduced chondrocyte proliferation, inappropriate chondrocyte maturation, and 
complete loss of osteoblasts (St-Jacques, Hammerschmidt & McMahon 1999). Although 
the secretion of IHH by chondrocytes is stimulated by IGF1 (Wang, Y et al. 2006; Yang, 
ZQ et al. 2017) and both IHH and IGF1 signalling pathways are involved in promoting 
chondrocyte proliferation in cartilage, the two pathways are thought to operate 
independently (Long et al. 2006). IHH binds the 12-pass transmembrane receptor, patched 
(PTC), and signals through the 7-pass transmembrane G-protein coupled receptor, 
smoothened (SMO), to mediate downstream IHH signalling (Zhang, XM, Ramalho-Santos 
& McMahon 2001). IHH signalling is mediated by the glioma-associated oncogene 
homologue (GLI) family of transcription factors (Hilton et al. 2005) (Figure 1.4). IHH 
stimulates chondrocyte proliferation through inactivation of the repressor function of GLI3 
in a PTHrP-independent manner, as demonstrated by the restoration of chondrocyte 
proliferation and reactivation of PTHrP expression in Ihh-/-Gli3-/- double mutant mice. IHH 
also inhibits chondrocyte hypertrophy via induction of PTHrP expression (Hilton et al. 
2005; Koziel et al. 2005).  
It is unclear what controls the expression of IHH in cartilage development; however, several 
studies have identified factors that may induce production of IHH. Treatment with T3 in 
Thsr-/- mice rescued expression of Ihh in the growth plate; and incubation of T3 also 
increased expression of Ihh in tibia rudiment culture (Xing et al. 2014). Addition of bone 
morphogenetic protein 2 (BMP2) leads an increase of Ihh expression in mouse limb 
explants, but it is not clear whether this is a direct or secondary consequence of BMP 
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regulation of Ihh expression (Minina et al. 2001). ATF4 directly binds to the Ihh promoter 
and regulates Ihh transcription in chondrocytes (Wang, W et al. 2009). Runt-related 
transcription factor 2 (RUNX2) directly induces Ihh expression, coordinating chondrocyte 
proliferation and differentiation (Yoshida et al. 2004). A recent study demonstrated that core 
binding factor beta (CBFβ) upregulates Ihh expression, as well as IHH target genes 
including CyclinD1 and Patched (Ptch1). CBFβ also downregulates the PTH/PTHrP 
receptor (Pthrpr) expression, thereby regulating chondrocyte proliferation and maturation 
(Tian et al. 2014).  
1.4.2.2.3 PTHrP, SOX9 and RUNX2 
PTHrP is expressed by perichondrial cells, resting and early proliferating chondrocytes, and 
is directly upregulated by IHH (St-Jacques, Hammerschmidt & McMahon 1999; Vortkamp 
et al. 1996). PTHrP maintains chondrocytes in a proliferative state and inhibits hypertrophic 
differentiation.  It diffuses to PTHrPR that is expressed by late PZ and pre-HZ chondrocytes 
and acts directly on proliferating chondrocytes. The prevention of hypertrophy regulated by 
PTHrP is driven via activation of transcription factor SRY-Box 9 (SOX9) that delays 
chondrocyte hypertrophy, and/or via inhibiting expression of transcription factor RUNX2, 
which stimulates chondrocyte differentiation (Dy et al. 2012; Guo et al. 2006; Huang, W et 
al. 2001). RUNX2 is also directly repressed by SOX9, which is consistent with their 
opposite functions on chondrocyte hypertrophy (Zhou, G et al. 2006). IHH and PTHrP form 
a negative feedback loop together with other factors including RUNX2 and SOX9 (Figure 
1.4). As previously mentioned, pre-HZ chondrocytes secrete IHH which induces production 
of PTHrP. By inhibiting hypertrophic differentiation through RUNX2 and SOX9, PTHrP 
limits the production of IHH-expressing chondrocytes, and thus regulates its own expression 
(Guo et al. 2006; Zhou, G et al. 2006). Increased PTHrP expression in hypothyroid rats and 
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suppression of PTHrPR expression in thyrotoxic rats suggest that T3 might regulate 
hypertrophy by inhibiting PTH/PTHrP signalling through PTHrPR (Stevens et al. 2000).  
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Figure 1.4 Interaction of growth factors and IHH/PTHrP signalling in growth plate. 
Parathyroid hormone-related peptide (PTHrP) is expressed by perichondrial chondrocytes. 
Indian hegehog (IHH) is synthesized by pre-hypertrophic chondrocytes. Arrows indicate 
stimulatory pathways, while crossed lines indicate inhibitory pathways. IGF1, insulin-like 
growth factor 1. Ptc, patched. Smo, smoothened. SUFU, suppressor of fused homologue. 
KIF7, kinesin family member 7. Gli, glioma-associated oncogene homologue. PTHrPR, 
parathyroid hormone related peptide receptor. Sox9, SRY-Box 9. Runx2, runt-related 
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1.4.2.2.4 BMPs, FGFs and WNT family 
Other groups of locally secreted factors, including bone morphogenetic proteins (BMPs), 
wingless-type mouse mammary tumor virus integration site (WNT) family proteins, and 
FGFs, also regulate growth plate chondrocytes and EO in a paracrine/autocrine pattern 
(Minina et al. 2002; Minina et al. 2001; Yoon et al. 2006). Activation of BMP signalling 
promotes proliferation of chondrocyte in the growth plate, induces IHH expression, and is 
involved in chondrocytes hypertrophy (Minina et al. 2001; Yoon et al. 2006). A recent study 
also suggested a role of GH in induction of BMP2 expression in growth plate chondrocytes 
(Wu, S et al. 2011). Such findings suggest that BMP and IHH/PTHrP signalling operate 
downstream to GH and interact with each other to coordinate chondrocyte proliferation and 
differentiation (Figure 1.2). FGFs function through fibroblast growth factor receptor 3 
(FGFR3), suppressing chondrocyte proliferation and inducing hypertrophic differentiation 
(Minina et al. 2002; Naski et al. 1998). FGF signalling has also been demonstrated to 
downregulate IHH/PTHrP signalling; however, its inhibition of proliferation is independent 
of IHH (Minina et al. 2002). The WNT family of secreted proteins is essential for 
proliferation, hypertrophy, survival and migration of chondrocytes during embryonic 
development and postnatal development (Akiyama et al. 2004; Yang, Y. et al. 2003). Target 
disruption of Wnt5a in mice revealed its role in preventing chondrocytes from entering 
proliferation, while WNT5b promotes cell proliferation (Yang, Y. et al. 2003). In addition, 
Hartmann and Tabin (2000) also found that WNT5a delays chondrocyte differentiation, 
whereas WNT4 expression promotes chondrocyte differentiation through β-catenin.  
During EO, many local signalling pathways, which act as a complex network through 
transcription factors, link circulating hormones and endocrine/paracrine factors together to 
regulate proliferation and differentiation of growth plate chondrocytes cells during both 
embryonic and postnatal growth. The GH/IGF1 system seems to be the most essential 
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pathway in regulating the proliferation of cartilage, whereas IHH, functioning in parallel to 
the GH/IGF1 axis, controls the balance between proliferation and hypertrophy either 
through PTHrP-independent or PTHrP-dependent pathways.  
1.4.2.3 GAGs and components of ECM 
Growth plate chondrocytes are also influenced by components of the ECM that comprises 
structural proteins such as proteoglycans and collagens and ECM-remodelling enzymes 
such as MMP13, MMP14 and MMP9 (Holmbeck et al. 1999; Inada et al. 2004; Mitchell et 
al. 1996; van der Eerden, Karperien & Wit 2003). Aggrecan, type II and type X collagens 
are the major ECM proteins expressed in the PZ and hypertrophic zone (HZ) of the growth 
plate, respectively (van der Eerden, Karperien & Wit 2003). A peptide secreted by type II 
collagen degradation induces chondrocyte hypertrophy and MMP13 and MMP14 
production, which is crucial for matrix remodelling and degradation (Tchetina et al. 2007).  
Several signalling pathways discussed above interact with GAGs and cartilage ECM. IHH 
directly interacts with chondroitin sulphate (CS) chains, binding to the major cartilage 
proteoglycan aggrecan, and the degree of sulfation of aggrecan modulates IHH signalling 
in the developing growth plate (Cortes, Baria & Schwartz 2009; Domowicz et al. 2009; Lin, 
X 2004). Heparan sulphate proteoglycans can interact with several BMPs, negatively 
regulating BMP signalling to interfere with cartilage differentiation during limb 
chondrogenesis (Fisher et al. 2006). Accumulation of GAGs in MPS may therefore 
contribute to the deregulation of such signalling pathways, and lead to disrupted EO and 
longitudinal bone growth.  
1.4.2.4 Factors involved in cell division cycle and apoptosis 
Chondrocytes rapidly proliferate under the guidance of certain signalling pathways such as 
IGF1, IHH, PTHrP, BMPs, FGFs and WNTs. Similar to other tissues and cells, proliferation 
23 | P a g e  
 
in chondrocytes requires strict control of the cell cycle by specific complexes that consist 
of cyclin-dependent kinase (CDK) and regulatory subunit cyclin, as well as cyclin-
dependent kinase inhibitors (CKIs) (LuValle & Beier 2000) (Figure 1.5). CyclinD1 triggers 
the exit from G0 phase and allow chondrocytes to enter the G1 phase, where they spend the 
greatest proportion of time. Cyclin D1 is highly expressed in cartilage, and is regulated by 
numerous growth factors and hormones, including WNT5a, WNT5b, IHH and PTHrP 
(Goodrich et al. 1991; Ito et al. 2014; Yang, Y. et al. 2003). CyclinD1 forms complexes 
with CDK4 and CDK6 that phosphorylate the pocket proteins (Retinoblastoma protein 
(pRb) and the closely related p107 and p130 proteins) (Calbó et al. 2002). The pocket 
proteins dissociate from a E2F complex, releasing E2F1, E2F2 and E2F3a, which serve as 
transcriptional activators and induce transcription of target genes that promote DNA 
replication (S phase), G2 phase and mitosis (M phase). S phase is the second longest phase 
of the cell cycle, in which the DNA replication of chondrocytes occurs. 
Activation of CyclinB-CDK1 complex is essential for entry to mitosis (Lindqvist, 
Rodríguez-Bravo & Medema 2009), during which chromatins condense into chromosomes. 
Phosphorylation of histone H3 is required for initiation of chromatin condensation, whereas 
at the end of mitosis, histone H3 is rapidly dephosphorylated (Hendzel et al. 1997). After 
several rounds of proliferation, chondrocytes receive anti-mitogenic signals during G1 
phase. Dephosphorylation of pocket proteins allows their association with E2F3b, E2F4 and 
E2F5, which forms complexes that function as transcription repressors that recruit histone 
deacetylases to promoters of target genes to inhibit their transcription (Gaubatz et al. 2000; 
Polgreen & Miller 2010). Inhibition of CDK activity by CKIs is then required for cell cycle 
exit upon onset of hypertrophic differentiation. Members of the CIP/KIP family (p27 and 
p57) are common CKIs expressed in the chondrocytes (Kiyokawa et al. 1996; Yan et al. 
1997).  
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Figure 1.5 Control of cell cycle progression. Progression of cartilage cells through the cell 
cycle is controlled by the activity of cyclins, cyclin-dependent kinases (CDKs) and CDK 
inhibitors (CKIs, such as p57kip2). Phosphorylation of pocket proteins regulated by 
CyclinD1/CDK4/6 complexes release E2F1 for entry into S phase. CyclinB1/CDK1 
complexes and phosphorylation of histoneH3 are essential for entry to mitosis and 
chromatin condensation, respectively. Cell cycle withdrawal for terminal differentiation is 
regulated by the balance of activator and repressor E2F proteins, which is under the control 
of CKIs, CyclinD1 and CDKs. 
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After the termination of chondrocyte hypertrophy, cells in the growth plate undergo cell 
death. Apoptosis has been proposed as one of the cell death mechanisms during EO 
(Lewinson & Silbermann 1992). Proteins involved in apoptotic activity include cysteine-
aspartic acid protease 3 (Caspase 3), anti-apoptotic gene B cell leukemia/lymphoma 2 
(BCL2), pro-apoptotic protein BCL2-associated X protein (BAX), TNF receptor 
superfamily member 6 (FASR) and FAS ligand (FASL). The activation of Caspase 3 is 
induced by the maturation of chondrocyte hypertrophy and results in cell death (Oltvai, 
Milliman & Korsmeyer 1993). The Bax/Bcl2 ratio determines cell survival or death after an 
apoptotic stimulus. Bcl2 expression is known to be regulated by PTHrP (Amling et al. 1997). 
Apoptosis is also triggered by activation of the FASR in FAS-expressing cells by the 
binding of the FASL (Ju et al. 1995). However, one study reported that FASL was absent 
in chondrocytes (Hashimoto et al. 1997).  
1.5 Growth plate dysfunction in MPS 
Investigation into growth plate dysfunction in MPS patients is limited to histological 
description at autopsy. Enlarged, vacuole-filled chondrocytes and a disorganised columnar 
structure have been observed in both MPS I and MPS IVA growth plates (McClure et al. 
1986; Silveri et al. 1991). 
Abreu et al.(1995) and Nuttall et al. (1999) found clusters of enlarged, GAG-containing 
cells in the growth plate, increased growth plate height with a poorly organized proliferating 
zone, loss of column formation in HZ, and an irregular number of osteoclasts in the cat MPS 
VI model. An increase in chondrocyte proliferation rate was observed in MPS VII dog 
growth plate (up to 5-fold faster than normal); however, most of the newly formed cells 
were immature and unable to mineralize into bone (Simonaro et al. 2005). A single study 
using MPS VII mice showed shortened bones, accumulation of the major GAG chondroitin-
4-sulfate (C4S), depletion of proliferating cell numbers, and reduction of chondrocyte 
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proliferation in cartilage growth plates (Metcalf et al. 2009). This study also found reduced 
phosphorylation of STAT3 (a pro-proliferative factor), reduced expression of activators for 
STAT3 phosphorylation and reduced expression of pro-proliferative gene Ihh, which may 
underly the reduced chondrocyte proliferation and shortened bones in MPS. 
To date, growth plate abnormalities that have been commonly observed in either patients or 
animal models are irregular growth plate structure, ballooned, vacuolated chondrocytes, and 
loss of columnar arrangement of chondrocytes in the PZ and HZ. 
1.6 Endocrine function and current GH therapy in MPS 
Although factors like GH, IGF1, T3 and IHH have been demonstrated to function in EO in 
linear bone growth, little information is known of their levels in MPS patients. Low serum 
IGF1 levels were detected in 3 untreated MPS II brothers (Toledo et al. 1991). Also, 
relatively low serum IGF1 levels were observed in 13 out of 22 MPS I patients post HCT 
(Gardner et al. 2011).  
Recombinant human GH has been used to treat short stature in children with various 
diseases (GH deficiency, idiopathic short stature, Turner syndrome and Prader-Willi 
syndrome) (Hardin 2008), with beneficial effects on skeletal and bone development. GH 
therapy has been used in post-HCT/ERT MPS children with conflicting results. hGH 
treatment (one year treatment) in MPSII and MPS VI patients with ERT and untreated MPS 
IV patients was initially shown to result in some improvement in growth velocity, spine 
correction, total body height and IGF1 level (Polgreen & Miller 2010). However, the study 
found no improvement of growth velocity in MPS IH (Hurler, severe form) or MPS II 
children with longer term GH treatment (two year treatment) (Polgreen et al. 2014). GH 
treatment for patients with GH deficiency (GHD) responded better than those without GHD. 
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In another study, minimal response to GH treatment was observed and treatment 
discontinued in 4 MPS IH children (Gardner et al. 2011).  
Hypothyroidism has also been reported in a case of MPS I patient with short stature 
(Mohanalakshmi, V. & S. 2014). Thyroid hormone substitution in the short stature of 
hypothyroidism has been applied for decades; however, there are currently no available 
reports of clinical trials of such therapy in MPS (Hermosa & Sobel 1972; Smith, RN, Taylor 
& Massey 1970). 
1.7 MPS VII mouse model 
Naturally occurring animal models of MPS are found in domestic, agricultural and wild 
species (Birkenmeier et al. 1989; Cowell et al. 1976; Haskins et al. 1984; Haskins et al. 
1979; Lorincz 1964; Spellacy et al. 1983; Thompson, JN et al. 1992). The development of 
naturally occurring animal models is similar to human MPS. However, not all types of MPS 
have corresponding naturally occurring animal models. Thus, transgenic and knockout 
models have been created to mimic specific mutations for which there is no spontaneous 
form (Clarke, LA et al. 1997; Evers et al. 1996; Garcia et al. 2007; Martin et al. 2008; 
Russell et al. 1998; Tomatsu et al. 2014; Tomatsu et al. 2003). However, although these 
models are genetically or biochemically similar to human MPS, some phenotypes such as 
skeletal deformities and short stature are mild or absent in transgenic and knockout animal 
modes (Clarke, LA et al. 1997; Garcia et al. 2007; Tomatsu et al. 2003).  
Mouse models are of great value in studying MPS as they are well-characterized inbred 
strains, many with a good representation of the pathology and clinical features of human 
MPS including skeletal deformities (Birkenmeier et al. 1989; Evers et al. 1996; Haskins et 
al. 1984). Murine models used in this study are MPS I mice (Clarke, LA et al. 1997), MPS 
IIIA mice (Roberts et al. 2009), attenuated form of MPS VII mice (Gustm(L175F)Sly) (Tomatsu 
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et al. 2002), and MPS IX mice (Martin et al. 2008). In addition, the naturally occurring 
murine MPS VII (Gusmps/mps) model is also employed (Birkenmeier et al. 1989). MPS I mice 
have sclerosis, thickened facial and long bones and joint diseases (Clarke, LA et al. 1997; 
de Oliveira et al. 2013; Russell et al. 1998). MPS IIIA mice have milder defects including 
thickened calvarium and vertebral deformation (Bhattacharyya et al. 2001; Bhaumik et al. 
1999). While MPS IX mice do not have obvious skeletal deformities except for altered 
matrix components in articular cartilage and in the growth plate (Martin et al. 2008). While 
these mouse models are normally used for investigating efficacy of therapies on lysosomal 
storage in brain and other organs, attenuated form of MPS VII mice (Gustm(L175F)Sly) and 
MPS VII (Gusmps/mps) model have been used to develop therapies for skeletal diseases 
(Derrick-Roberts et al. 2016; Derrick-Roberts et al. 2014; Macsai et al. 2012) 
The majority of this study utilises the severe strain MPS VII (Gusmps/mps). The MPS VII 
(Gusmps/mps) mouse mutation maps to the distal half of chromosome 5, the region 
homologous to human chromosome 7 (Schwartz et al. 1991). A 1bp deletion in exon 10 
results in the formation of a premature stop codon, leading to the complete lack of β-
glucuronidase activity and accumulation of the DS, HS, C4S and C6S (Sands & Birkenmeier 
1993). MPS VII (Gusmps/mps) mice are physically distinguishable from normal littermates by 
7 days of age by their smaller body size, shorter limbs, shorter and thicker tail and facial 
dysmorphism (Figure 1.6) (Birkenmeier et al. 1989). Lifespan is reduced and affected mice 
die by 6-7 months of age.  
  
29 | P a g e  
 
Figure 1.6 Six-month-old normal mouse (left) and MPS VII (Gusmps/mps) mouse (right). 
(A) Visual facies; (B) visual bodies and (C) X-ray of mouse models. Figures are derived 
from Matrix Biology Unit, SA pathology. Scale bar=5cm. 
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1.8 Aims 
Growth plate dysfunction has been identified as the most likely cause of bone shortening in 
MPS. Growth plate cartilage cells of normal children respond to circulating hormones such 
as GH and T3. These factors either directly act on chondrocytes, or triggers 
activation/inhibition of downstream paracrine/autocrine factors and transcription factors as 
well as cell cycle regulators that promotes proliferation and differentiation of chondrocytes 
in the growth plate. While the regulations of chondrocyte proliferation and differentiation 
involve a complex network, it is possible that the reduced proliferation in the MPS VII 
growth plate results from multiple impaired signalling pathway. 
This study therefore aims to characterise bone development and growth plate maturation 
and to determine potential pathways that are affected in MPS during these processes using 
a naturally occurring MPS VII murine model. With an improved understaning the 
underlying mechanism, potential intervention point(s) for therapy could be highlighted to 
improve growth in MPS.  
The specific aims are: 
1. To characterise the development of bone growth in different MPS mouse models 
(MPS I, IIIA, VII (Gusmps/mps and Gustm(L175F)Sly and IX) 
2. To investigate the regulation of EO through cell cycle in MPS VII mice  
3. To investigate the regulation of bone growth at endocrine level in MPS VII mice 
4. To investigate the relationship between local signalling pathways and growth plate 
dysfunctions in MPS VII mice  







2 Materials and Methods 
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2.1 Materials 
Materials used are listed in the Appendix A.  
2.2 Animal husbandry and genotyping 
All experimental procedures were approved by the Womens and Childrens Health Network 
and the University of Adelaide Animal Ethics Committees. Founder animals for MPS I, 
MPS IIIA, MPS VII (Gusmps/mps strain) and attenuated MPS VII (Gustm(L175F)Sly strain) were 
obtained from Jackson Labs while MPS IX founder mice were obtained from Mutant mouse 
resource & research centers (MMRRC). MPS and normal mice were bred from 
heterozygous parents with the same background in each case. Homozygous normal mice 
from were used as normal control. Mice were housed in a 14/10 light/dark cycle with food 
and water ad libitum.  
Genomic DNA was extracted from tissue by lysis in Viagen lysis buffer containing 0.4 
mg/mL proteinase K as per the manufacturer’s instruction (Viagen Biotech Inc., USA). A 
polymerase chain reaction (PCR) based genotyping protocol was performed on genomic 
DNA as previously described (Clarke, LA et al. 1997; Derrick-Roberts et al. 2014; Macsai 
et al. 2012; Martin et al. 2008; Roberts et al. 2009).  
2.2.1 Mouse sacrifice and tissue harvest 
Mice were humanely killed at experimental end points by carbon dioxide asphyxiation 
followed by cervical dislocation before blood was collected via cardiac puncture or 
retriobital bleed. Blood was stored at 4°C overnight before serum was separated by 
centrifugation at 800 x g for 10 minutes and stored at -80°C for future analysis. Liver tissue 
was collected and fixed in 10% neutral buffered formalin and embedded in paraffin for 
immunohistochemical analysis or stored at - 80°C for real-time PCR analysis. Hindlimbs 
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and L4-L6 vertebrae were removed and fixed in 10% buffered formalin overnight and then 
stored in 70% ethanol for radiography. Hindlimbs were embedded in paraffin for 
histological, histomorphometrical and immunohistochemical analysis. The proximal tibia 
growth plates from 14 days old (P14) normal and MPS VII mice were isolated, snap frozen 
and then stored at -80°C for later real-time PCR analysis, or snap frozen in optimal cutting 
temperature compound (OCT) and then stored at - 80°C for microdissection.  
2.3 Bone and growth plate histomorphometric measurementRadiography and bone 
length measurements 
Femurs, tibiae and L4-L6 vertebrae were harvested from 6-month old normal and MPS mice 
and X-rayed as previously described to compare bone length of 5 mouse models at maturity 
(Derrick-Roberts et al. 2014). Additional radiographs of femurs from MPS I, MPS VII 
(Gusmps/mps strain) and attenuated MPS VII (Gustm(L175F)Sly strain) mice along with normal 
littermates were taken at P14, 1 month, 2 months and 3 months of age to determine the 
natural history of linear bone growth in MPS. X-ray films were scanned, converted to digital 
data using the GE healthcare radiograph system Discovery XR656 (GE healthcare, 
Australia). Digital radiographs were calibrated and femur, tibia and L5 vertebrae lengths 
were measured from the most proximal point to the most distal points of articular surface of 
the bones using Olympus analySIS® LS Research Olympus Soft Imaging Solutions version 
3.1 (Olympus Australia Pty. Ltd., Gulfview Heights, SA). The number of mice of each 
genotype and age are presented in Table B.1 of Appendix B. 
2.3.2 Proximal tibia morphology 
Knee joints were removed from normal and MPS mice and fixed in 10% neutral buffered 
formalin for 24 hours and then decalcified in ImmunocalTm between one day (E17.5 and 
E18.5 samples) and 4 weeks (postnatal samples) prior to routine processing and embedding 
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in paraffin blocks. Five microns sections were cut using a Leica RM2235 microtome (Leica 
Microsystems Pty Ltd, NSW, Australia) and stained with a modified safranin-O/ fast-green 
protocol (Rosenberg 1971). Consecutive sections deparaffinized using Solv21C (United 
Bioscience, VIC, Australia), 100% ethanol, 70% ethanol and dH2O and then stained for 5 
min in 0.07% fast-green stain. Sections were rinsed with 1% acetic acid then stained in 
0.07% safranin-O. Sections were dehydrated in 70% ethanol, 100% ethanol and 
subsequently in xylene. Stained samples were mounted using Leica CV Mounting Media. 
2.3.3 Quantification analysis of area occupied by secondary ossification centre growth 
plate zone height, and chondrocyte number and size. 
Sections collected from each animal that have the largest area occupied by the SOC was 
considered as the midsagittal plane. Sections were stained with safranin-O/fast green. The 
area occupied by the SOC contains marrow elements and bones (stained green by Fast 
Green) and is defined as Figure 2.1. The area occupied by the SOC and total area of the 
proximal epiphysis were measured using an Olympus BX51 microscope (Olympus 
Australia Pty. Ltd., Gulfview Heights, SA). and Olympus analySIS® LS Research Olympus 
Soft Imaging Solutions (version 3.1) software and results of area occupied by the SOC were 
represented as percentage of total epiphysis area.  
Individual growth plate zones were defined using morphological criteria as previously 
described (Nuttall et al. 1999). The RZ consisted of round, single chondrocytes; the 
proliferating zone adjacent to the RZ was characterized by flattened cells arranged into 
multicellular clusters to form columns of chondrocytes perpendicular to the growth axis. 
The HZ was considered to start at the point at which chondrocyte size had doubled and 
terminated at the metaphysis. Zone height was measured at 100 μm intervals across the 
growth plate for a total of 8 measurements in P14 mice and 16 measurements in 1 and 2 
months old mice. Measurements were averaged to yield a single value for each zone for 
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each animal. The total height of the proximal tibial growth plate was determined by 
summing the heights of the RZ, PZ and HZ. Distinct zones were difficult to define in 6-
month old mice and thus individual zone heights were not measured. The total growth plate 
height in 6 months old mice was taken as the distance between the epiphysis and metaphysis, 
with 16 measurements taken at 100 μm intervals across the growth plate and averaged for 
each animal. Eight, sixteen and eight 50 µm x 50 µm squares were randomly selected in the 
RZ, PZ and HZ respectively of each animal. The number of chondrocytes within each square 
was measured. Chondrocyte number in each square of each zone was averaged to give the 
final value per animal. Since lacunae are presumed to represent expanded cell size (Orkin 
et al. 1977), the horizontal diameter of each chondrocyte lacuna within each square was 
measured to determine the size of chondrocytes and was averaged per animal. 
 
Figure 2.1 Histologic structure of the proximal end of normal and MPS VII mice tibia 
at 1 month of age. Safranin O/fast green stained proximal tibia section of normal (A) and 
MPS VII (B) mice. The region from the edge of articular surface to the last cells of the 
hypertrophic zone of the growth plate represents the epiphysis. The region within the 
epiphysis represents the developing SOC, which was measured as the area occupied by 
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2.4 Transmission electron microscopy (TEM) 
Tibia from normal and MPS VII mice aged P14 were fixed in Karnovsky’s fixative 
supplemented with 0.7% (v/v) safranin O (Wilson, R et al. 2010) for 2 hours and then 
decalcified for 7 days in 14% EDTA (pH 7.4) with 0.1% glutaraldehyde. Tibia were post 
fixed in 2% osmium tetroxide, processed and embedded in Araldite-Procure resin (Pelco 
BioWave; Pelco International) (Derrick-Roberts et al. 2014; Kopecki et al. 2009; Macsai et 
al. 2012). Semi-thin (1 µm) sections were stained with 1% toluidine blue in 1% borax for 
orientation. Ultrathin (80 nm) sections were cut on a Leica UltraCut S Ultramicrotome 
(Leica system, Germany) with an ultra-diamond knife. The sections were mounted on 
copper grids and stained with uranyl acetate and lead citrate for 7 minutes. The ultrathin 
sections were examined with a Tecnai G2 Spirit transmission electron microscope (FEI, 
Eindhoven, the Netherlands) equipped with a VELETA CCD camera (Olympus SIS, 
Münster, Germany) at Adelaide Microscopy (Adelaide, Australia) and EDS system 
comprising an Apollo XLT SDD running EDAX's TEAM software were used. The 
chondrocytes in the RZ, PZ and HZ of tibia growth plate were assessed using TEM in both 
normal and MPS VII mice.  
2.5 Measurement of circulating hormones 
Blood was collected from mice at P14, 1, 2 and 6 months of age via cardiac puncture. Serum 
was prepared as described in section 2.2.1 and stored at -80°C. Measurement of circulating 
levels of GH, IGF1, IGFALS, IGFBP3, T3 and IHH in normal and MPS VII serum was 
performed using ELISA kits according to manufacturer’s instruction (Appendix A). 
2.6 GH production 
Normal and MPS VII mice (1, 2 and 4 months of age) were anaesthetized with ketamine 
(75 μg/gm body weight) and dormitor (1 μg/gm body weight) combination. GH secretion 
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was stimulated by the intraperitoneal injection of ghrelin at 10 μg/animal. Control mice 
received saline instead of ghrelin. Blood was collected by retro-orbital bleeding at 0, 5 and 
15 minutes after injection. Serum was prepared as described in section 2.2.1 and stored at -
80°C prior to GH level determination by ELISA as above. GH level of serum collected at 0 
minutes after injection was considered as baseline level. GH release at 5 and 15 minutes 
after ghrelin injection was compared to baseline level to assess the stimulatory effect of 
ghrelin  
2.7  IGF1 production 
2.7.1 Isolation and in vitro culture of primary hepatocytes 
Seven-week old normal and MPS VII mice were anesthetized as described in section 2.2.1. 
and the peritoneal cavity was opened. The liver was perfused with pre-warmed perfusion 
medium I (PBS containing 1M HEPES, 5%(w/v) KCl, 1M glucose, 200 mM EDTA, pH 
7.4), and then with perfusion medium II (PBS containing 1M HEPES, 5%(w/v) KCl, 1M 
glucose, 500 mM CaCl2, pH 7.4 containing 0.8 mg/ml collagenase type I). Digested liver 
was removed and rinsed with perfusion medium II and then gently teased with forceps and 
scissors until cells were released in solution. The cells were filtered through a sterile 70 μm 
nylon cell strainer (Corning Inc, Durham, USA) to remove excess tissue. The cells were 
then washed and centrifuged for 5 minutes at 50 x g in perfusion medium II three times 
using Beckman Coulter optima L-100K ultracentrifuge and SW60 rotor. Cell pellet was 
resuspended in Williams E medium containing 1% 5,000 U/mL penicillin and 5,000 µg/mL 
streptomycin (P/S), 1% 200mM L-glutamine, 1% nonessential amino acids and 10% heat-
inactivated FCS. The yield and viability of hepatocytes was determined using the 
Countess® automated cell counter and 0.4% trypan blue (Invitrogen, Life Technologies, 
Australia). and the yield of hepatocytes ranged between 100-400 million cells per animal, 
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with a viability at 85-95% for all experiments. A 24-well plate was coated with Geltrex 
LDEV-Free hESC-qualified reduced growth factor basement membrane matrix at a 
concentration of 1:10 in Williams E medium containing 1% P/S, 1% 200 mM L-glutamine, 
1% nonessential amino acids and 10% heat-inactivated FCS. Each well was seeded with 
1x105 hepatocytes and incubated at 37°C, 5% CO2. After 24h, non-adherent cells were 
removed by aspiration and Williams E medium containing 1% P/S, 0.5mg/ml gentamycin, 
0.04% fungizone, 20mM L-glutamine and 1% nonessential amino acids was added.  
2.7.2 Production of IGF1 in response to stimulation 
Triplicate wells were incubated with recombinant GH at a final concentration of 0 ng/ml, 
10 ng/ml, 50 ng/ml, 100 ng/ml, 500 ng/ml and 1000 ng/ml. Medium was collected and stored 
at -20°C for later IGF1 measurement by ELISA as described in section 2.6.2. The cell layer 
was harvested for enzyme activity assay (Section 2.7.3) by 0.25% trypsin/EDTA and cell 
lysed by freeze-thaw in 0.1% Triton X100. Total protein was measured using Bradford assay 
according to manufacturer’s instruction.  
2.7.3 β-glucuronidase production and administration to MPS VII hepatocytes 
A lentiviral vector was constructed to encode mouse β-D-glucuronidase (pHIV-
EF1αmmGUS) as previously described (Jackson et al. 2015). β-glucuronidase was produced 
in CHO-K1 cells. Briefly, CHO-K1 cells were seeded in Hams F12+10%FCS at 5.5x104 
cells/cm2 and transfected 3 h later with the addition of 0.75 μg/ml p24 protein of pHIV-
EF1αmmGUS in the presence of 8ng/ml polybrene and 100ng/ml gentamycin. After 24h 
the media was removed and replaced with Hams F12 medium containing 1% P/S and 1% 
200mM L-glutamine. Medium collected was pooled and concentrated by centrifugation on 
a YM-30 Centricon filter (Amicon,USA). β-glucuronidase enzyme activity from 
concentrated medium was determined using the fluororgenic substrate 4-
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methylumbelliferyl-b-D-glucuronide (Derrick-Roberts et al. 2014; Macsai et al. 2012) on a 
LS 50B luminescence spectrometer using an AS 91 auto-sampler (Perkin Elmer, Waltham, 
Massachusetts, USA) at excitation  and emission wavelength of 366nm and 446nm, 
respectively. 
Hepatocytes isolated from MPS VII mice were incubated in Williams E medium containing 
1% P/S, 0.5 mg/mL gentamycin, 0.04% fungizone, 1% 200mM L-glutamine and 1% 
nonessential amino acids alone (control) or in the medium containing 0.04 nmol/min β-
glucuronidase, while hepatocytes isolated from normal mice were incubated in Williams E 
medium containing 1% P/S, 0.5% gentamycin (10mg/mL), 0.04% fungizone, 1% 200 mM 
L-glutamine and 1% nonessential amino acids alone at 37°C, 5% CO2 for 24 h. 500 ng/mL 
recombinant mouse GH was added to primary hepatocyte culture (section 2.6.1.2). 
Hepatocytes were cultured for additional 24 h at 37°C, 5% CO2. Medium was collected and 
stored at -20°C for later IGF1 measurement by ELISA as described in section 2.6.2. β-
glucuronidase enzyme activity from cells was determined using the fluorogenic substrate 4-
methylumbelliferyl-b-D-glucuronide (Derrick-Roberts et al. 2014; Macsai et al. 2012). 
2.8 Response of chondrocytes to systemic or local factors  
2.8.1 Isolation and in vitro culture of primary chondrocytes 
The proximal tibia growth plate was dissected out from P14 normal and MPS VII mice 
(Figure2.1) free of perichondrium, POC and SOC. Growth plate was collected into Hams 
F-12 medium and the incubated in Hams F-12 containing 1% (w/v) pronase and 1% P/S at 
37ºC for 1 hour. Tissue was washed with PBS to remove pronase and incubated in Hams F-
12 containing 0.08% (w/v) collagenase, 5% FCS and 1% P/S at 37ºC for at least 15 h. Cells 
were filtered through a 50μm nylon filter and collected by centrifugation at 1500 rpm for 5 
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min. Cell number was determined using the Countess® automated cell counter and 0.4% 
trypan blue. 
2.8.2 Cell proliferation assay  
To determine cell proliferation, chondrocytes were seeded at 6.25x104 cells/cm2 in a 96-
well plate and maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 1% 
P/S, 1% FCS. The dose to GH, T3, IGF1 and IHH was determined in normal chondrocytes 
on day 2 of culture. Recombinant mouse GH reconstituted in dH2O at 1 mg/ml and added 
to chondrocyte cultures to give a final concentration of 50 ng/mL, 100 ng/mL, 200 ng/mL, 
250 ng/mL, 500 ng/mL, and 1000 ng/mL. Recombinant mouse IGF1 and recombinant 
human/mouse were reconstituted in dH2O at 100 µg/ml and added to chondrocyte cultures 
to give a final concentration of 25 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, 250 ng/mL 
and 500 ng/mL. T3 was dissolved in 1M NaOH at 1mg/mL and added to chondrocyte 
cultures to give a final concentration of 1 ng/ml, 10 ng/ml, 50 ng/ml, 100 ng/ml, 250 ng/ml, 
500 ng/ml. The CyQUANT® Direct Cell Proliferation Assay Kit was used for assessment 
of cell proliferation. Cells were lysed according to manufacturer’s instruction, and total 
cellular nucleic acid was measured using florescence (485nm excitation, 535nm emission, 
0.1sec) on a VICTOR2 plate reader (Perkin Elmer). Dose-response results are shown in 
Figure 2.2 and the following concentrations used in subsequent experiments: 250 ng/mL 
GH, 500 ng/mL IGF1, 25 ng/mL IHH and 10 ng/mL T3. Normal and MPS VII chondrocytes 
were cultured in DMEM containing 1% P/S, 1% FCS, with the presence of 250 ng/mL GH, 
500 ng/mL IGF1, 10 ng/mL T3 or 25 ng/mL IHH. On day 0, 2, 4, and 6, cell proliferation 
was assessed. The negative control consisted of cells incubated in DMEM containing 1% 
P/S plus 1% FCS. The positive control consisted of cells incubated in DMEM containing 
1% P/S plus 10% FCS.  
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Figure 2.2 Dose-response effects of hormones on normal chondrocytes. Cell 
proliferation of triplicate samples was measured 2 days after addition of A) GH, (B) T3, (C) 
IGF1 and (D) IHH.  
* denotes a p<0.05 significant difference between GH, T3, IGF1 or IHH treated and 
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2.8.3 IHH secretion by chondrocytes 
To assess the secretion of IHH by chondrocytes, cells were seeded at a density of 1x105 
cells/cm2 on 24-well plates and maintained in DMEM containing 1% P/S and 1% FCS for 
48h and 96h. Medium were collected and assayed for IHH expression using commercially 
available ELISA kits as above (Section 2.5).  
2.9 Gene expression analysis 
Liver from 14 days old normal and MPS VII mice was dissected. The proximal tibia growth 
plate from 14 days old normal and MPS VII mice was dissected clear of bone and 
surrounding perichondrium. For gene expression analysis in the liver and whole growth 
plate, samples were snap-frozen in liquid nitrogen and stored at -80 ºC until RNA isolation. 
Liver tissues were homogenized using a Potter-Elvehjem test pestle (Sigma, NSW, 
Australia) in Trizol reagent and RNA isolated according to manufacturer’s instruction. 
Whole growth plates were finely ground in liquid nitrogen, homogenized by passage over a 
QIAshredder column (Qiagen, Maryland, USA) and RNA isolated using the RNaqueous® 
Micro Kit including a DNaseI digestion. The PZ was also manually microdissected from 
the proximal tibia growth plate of D14 mice using a method from (Belluoccio et al. 2008) 
with modification from zone specific analysis. Briefly, whole growth plates were snap 
frozen in OCT compound using pre-cooled isopentane in liquid nitrogen and stored at -
80°C. Twenty microns longitudinal sections were cut using a Leica CM1800 Cryostat 
(Leica Microsystems Pty Ltd, NSW, Australia), pre-cooled to -22°C (maintained between -
20 and 23°C) and mounted on RNase-free Superfrost Plus glass slides (Lomb Scientific Pty 
Ltd, NSW, Australia). Slides were fixed in 70% EtOH in diethylpyrocarbonate (DEPC) 
treated water for five minutes with regular agitation and dehydrated through serial ethanol 
wash and dried on 50°C hot plate for 5 seconds. Slides were then immobilized on Nikon 
SMZ25 stereo microscope and the PZ dissected using an ophthalmic knife (MVR20, Mani 
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Inc., Tochigi, Japan). The tissue was harvested into an RNase-free tube and total RNA was 
isolated using TRIzol reagent according to the manufacturer’s instruction. The 
concentration of RNA isolated by either procedure was determined using a Thermo 
Scientific NanoDrop 1000 and its operating software, version 3.8.1 (Thermo Scientific, 
VIC, Australia).  
Approximate 200 ng of the isolated RNA was reverse transcribed into cDNA using the 
QuantiTect® Reverse Transcription Kit. Quantitative real-time PCR was performed on an 
ABI 7300 real-time PCR system (Applied Biosystems, Life Technologies, California, USA) 
using SYBR® Green Master Mix. Primers used were listed in Appendix B Table B5. The 
thermal cycling conditions comprised the initial steps at 50 ºC for 2 minutes, and 95ºC for 
10 minutes. Amplification of cDNA consisted of a denaturation step at 95ºC for 15 seconds, 
and an extension step at 60ºC for 1 minute. A dissociation stage consisting of a cycle of 15 
seconds at 95ºC, 30 seconds at 60ºC, and 15seconds at 95ºC was added. Data were 
normalized to cyclophilinA (CycA) and the fold change was calculated using the ΔΔCt 
method (Livak & Schmittgen 2001). For samples collected from the manual microdissection 
of the PZ, markers of the RZ (Pthrp) and HZ (Mmp13) were analyzed to check for the 
accuracy of isolation of PZ chondrocytes.   
2.10 Immunohistochemistry 
P14 normal, MPS VII and MPS IIIA proximal tibiae (n=3 per genotype, except for detection 
of phosphor Ser10 histone H3 (phos-hisH3), n=5 MPS VII tibiae were used) were fixed in 
10% neutral buffered formalin, decalcified in ImmunocalTm and embedded in paraffin. 
Livers from P14 normal and MPS VII (n=5 per genotype) were fixed in 10% neutral 
buffered formalin and embedded in paraffin. Testis from 2m normal mice were fixed in 10% 
neutral buffered formalin and embedded in paraffin. Five-micron sections were collected 
from each tissue sample. Immunohistochemisty was carried out on tibia or liver sections 
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after deparafinization and antigen retrieval as described in Table 2.1. Rabbit IgG antibody 
was used as negative control except for detection of IHH. 10 µg/ml IHH antibody was 
incubated with 40 µg/ml recombinant IHH as absorption control. Mouse testis sections were 
used as positive control (data not shown).  
Blocking solutions and biotinylated secondary antibody were as per the Cell and Tissue 
Staining Kit (anti-rabbit or anti-goat) for all antibodies except phos-hisH3. For phos-hisH3, 
tibia sections were blocked with 5% normal horse serum and incubated with goat-anti-rabbit 
fluorescein isothiocyanate (FITC) secondary antibody (1 in 1000 dilution). Sections were 
counterstained with Mayer’s hematoxylin or Prolong-Gold DAPI (P36931, ThermoFisher, 
Australia) and evaluated under an Olympus BX51 microscope fitted with Soft Imaging 
System’s Colorview III camera and analySIS® LS software. The number of cells staining 
positive for Caspase 3, phos-hisH3, Ki67, p57kip2, CyclinB1, Cyclin D1, phosphorylated 
pRb (phos-pRb), phosphorylated p130 (phos-p130), E2F1, E2F4, GHR, IGF1 and IHH in 
each zone was determined using Olympus analySIS® LS Research Olympus Soft Imaging 
Solutions (version 3.1) software. The number of chondrocytes within a 200μm wide strip 
that encompassed all zones was determined and repeated twice more. Chondrocyte number 
in each zone was averaged to give the final value per animal and presented as a percentage 
of the total number of cells per area counted. For immunostaining analyses of GHR, tyrosine 
phosphorylated-JAK2 (Y-phos-JAK2), -STAT5 (Y-phos-STAT5), -STAT5A (Y-phos-
STAT5A), and serine phosphorylated-STAT5 (S-phos-STAT5) on liver sections, captured 
images were analyzed using Image J with a compatible IHC profiler plugin for analyzing 
cytoplasmic and nuclear staining pattern (Chatterjee et al. 2013; Varghese et al. 2014).  
2.11 Statistics 
The number of animals used in bone morphology, endocrine level measurement and IHC 
analysis was justified based on previous lab studies and literatures (Derrick-Roberts et al. 
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2016; Derrick-Roberts et al. 2014; Macsai et al. 2012; Metcalf et al. 2009; Sun et al. 2004). 
The number of animals used for gene expression analysis and local regulation of 
chondrocytes was justified with power analysis p<0.05 and power=80%. Statistical 
significance of variance (age and diseases state as independent variables) was determined 
by a two-way ANOVA with a Tukey’s HSD post-hoc analysis using GraphPad Prism 
version 7.0 (GraphPad Software Inc., California, USA). Statistical significance of variance 
(diseases as variables) was determined by a Student’s t-test using Microsoft Excel 2010 and 
2016. Statistical significance was assumed when p<0.05. 
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Table 2.1 Antigen retrieval and dilution used for primary antibodies in 
immunohistochemical analysis. 
Antibody Source and cat # Antigen retrieval Dilution  
Activated caspase 3 
(Asp175) 
CST #9661 10mM sodium citrate 





Caspase 3 CST #9662 1:1000 
Cyclin D1(SP4) ThermoFisher MA5-
14512 
10mM sodium citrate 




E2F1  Abcam ab179445 
pRb (phospho S780) Abcam ab47763 
Cyclin B1 (H433) Santa Cruz sc-752 1:100 
 E2F4 Abcam ab53060 
STAT5 (phospho 
Y694/Y699) 




IHH N-terminus R&D system AF1705 1:20 
JAK2(phosphor 
Y1007/Y1008) 
Abcam ab32101 1:25 
GHR Abcam ab202964 1:200 
 Histone H3 (phosphor 
Ser10) 
CST #9701 








Isotype (IgG) Abcam ab27478 
 
 
Antibodies were purchased from Santa Cruz Biotech, USA, ThermoFisher, USA, Abcam, 
Australia, Cell Signalling (CST), Danvers, MA, USA and R&D system, USA. 
  








3  Development of bone pathology in MPS mouse 
models 
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3.1 Introduction 
MPS, a group of lysosomal storage disorders, are caused by a single enzyme deficiency. 
Reduced longitudinal bone growth leading to short stature is a common feature observed in 
MPS I, II, IVA, IVB, VI and VII patients (Melbouci et al. 2018; Neufeld & Muenzer 2001). 
Although children may fall within the normal height (length) range at birth, their growth 
progressively slows, and they fall below the third percentile for height by two to three years 
of age (Hendriksz et al. 2013; Montaño et al. 2008; Neufeld & Muenzer 2001) as GAG 
accumulates in connective and skeletal tissues. Longitudinal bone growth in MPS is not 
amenable to current therapies, including BMT/HSCT, or ERT. Genes and underlying 
mutations in human MPS have been well characterised; however, the pathological cascade 
in MPS bone growth initiated by accumulated lysosomal storage is poorly understood, thus 
limiting the development of therapies.  
Animal models of MPS, either naturally occurring or via targeted disruption of genes 
encoding lysosomal enzymes of GAG degradation, have been employed to study bone 
pathology in MPS (Abreu et al. 1995; Birkenmeier et al. 1989; Crawley et al. 1997; Herati 
et al. 2008; Macsai et al. 2012; Metcalf et al. 2009; Nuttall et al. 1999; Schuchman et al. 
1989). Although skeletal deformities in some of these MPS animal models have been 
characterized, the growth pattern of long bones of MPS animals has not been detailed. The 
aim for this chapter was to characterise the development of bone growth in five MPS mouse 
models (MPS I, MPS IIIA, MPS VII (Gusmps/mps (severe) and Gustm(L175F)Sly  (attenuated) 
strains) and MPS IX). This chapter hypothesize that these five mouse models mimic their 
corresponding human MPS, that is, MPS I and MPS VII (Gusmps/mps (severe) and 
Gustm(L175F)Sly  (attenuated) strains) mice have shortened long bones, while MPS IIIA and 
MPS IX mice have normal bone length. A detailed time-course of the endochondral bone 
development was performed, as well as further characterization of growth plate 
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abnormalities in the severe MPS VII mouse model (Gusmps/mps) using histomorphometric 
analyses. 
3.2 MPS VII mouse models are good representatives of the corresponding human 
MPS for short stature 
MPS I, MPS IIIA, MPS VII (Gusmps/mps and Gustm(L175F)Sly  strains) and MPS IX femur 
(Figure 3.1A), tibia (Figure 3.1B) and L5 vertebra (Figure 3.1C) lengths were measured on 
radiographs of 6-month old mice (Chapter 2.3.1). Femur length was significantly decreased 
in murine MPS I, MPS VII severe strain (Gusmps/mps) and MPS VII attenuated strain (Gustm 
(L175F)Sly) reaching 95.5±0.7%, 92.6±1.1%, and 66.8±1.3% of normal length respectively. 
MPS IIIA and MPS IX femur lengths were not different to normal, being 100.2±0.7% and 
99.0±2.3% of normal at maturity, respectively. Tibia lengths were significantly reduced in 
murine MPS VII severe strain (Gusmps/mps) and MPS VII attenuated strain (Gustm (L175F)Sly), 
reaching 80.9±3.3% and 96.3±0.6% of normal length respectively. Tibia lengths were the 
same as normal in murine MPS I, MPS IIIA and MPS IX.  L5 vertebra height was 
significantly decreased only in the murine MPS VII severe strain (Gusmps/mps), reaching 
85.6±1.6% of normal. There was no difference in L5 height between murine MPS I, MPS 
IIIA, attenuated MPS VII (Gustm(L175F)Sly ), MPS IX strains and normal mice.  
Femoral and tibial growth in the 3 models that displayed growth retardation was further 
analyzed from 14 days of age until 6 months of age (Chapter 2.3.1). Murine MPS VII 
(Gusmps/mps) differed from their normal littermates in showing marked decrease in femoral 
(Figure 3.2A) and tibial length (Figure. 3.2 D) from 14 days of age onwards. Femur lengths 
of MPS VII severe strain (Gusmps/mps) were 83.5±3.2% of normal at 14 days of age (p<0.05) 
and were progressively decreased from this age onwards. Tibia length of MPS VII severe 
strain (Gusmps/mps) were 91.0±2.9% of normal (p<0.05) at 14 days of age and were also 
significantly shorter than normal mice from this age onwards. Femoral and tibial growth 
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rates of these mice from 14 days to 1 month of age were significantly decreased to 
77.0±7.0% and 57.0±6.3% of normal (p<0.05). The femur of attenuated MPS VII (Gustm 
(L175F)Sly) mice were significantly shortened from 3 months of age onwards (Figure 3.2E). 
The defect appeared earlier at P14 in the tibia of the same animals (Figure 3.2H). However, 
differences in growth velocity of the femur and tibia between attenuated MPS VII and 
normal mice did not reach statistical significance (Figure 3.2J). Bone shortening in murine 
MPS I was observed only in femur at 3 months and 6 months of age (Figure 3.2F and I). 
Not surprisingly, femoral and tibial growth rate of MPS I mice were not significantly 
different to those in normal mice from the same colony (Figure 3.2J). 
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Figure 3.1 Mature bone length of MPS murine models. Femur (A) and tibia length (B) 
and L5 vertebrae height (C) presented as a percentage of age-matched normal bone length 
in MPS I, IIIA, MPS VII (Gusmps/mps), MPS VII mice (GustmSly(L175F)) and MPS IX mice at 
6-month of age. Results are expressed as the mean ± S.E.M. The number of animals used 
was listed in Table B1 of Appendix B.  
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Figure 3.2 Quantitative analysis of longitudinal bone growth in MPS murine models. 
Femur (A-C) and tibia (D-F) length in MPS I, MPS VII (Gusmps/mps) and MPS VII mice 
(GustmSly(L175F)) from P14 to 6 months of age. (G) Growth rate (% of normal) of MPS mice 
during P14 to 1 and 1 to 2 months of age. Mean ± S.E.M. The number of animals used was 
listed in Table B1 of Appendix B.  












































































































































Femur growth rate Tibia growth rate
0.5-1m 1-2m 0.5-1m 1-2m
Gusmps/mps 77±7%* 50±2.5%* 57±6%* 39±5%*
Gus tm(L175F)Sly 130±6% 83±9% 107±4% 61±3%*
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3.3 MPS VII epiphyseal and diaphyseal morphology during embryonic and early 
postnatal stages 
3.3.1 MPS VII mice exhibit delayed endochondral bone formation and thickened 
growth plate 
Bone length was already significantly reduced in MPS VII (Gusmps/mps), hereafter referred 
to as MPS VII mice, at 14 days of age (Figure 3.1A and D) To gain insights into the 
differences in bone development between normal and severe MPS VII mice, safranin-O/fast 
green stained sections of proximal tibiae (Chapter 2.3.2) were assessed from embryonic 
stage E12.5-17.5, (Figure 3.3A) to postnatal 6 months (Figure. 3.3C). Between E12.5 to 
E13.5, mesenchymal condensation to chondrocytes in the presumptive tibia was observed 
(Figure. 3.3A and B). One day after, chondrocytes became hypertrophic at the site of the 
future POC. Sections through the tibia of MPS VII mice showed no apparent difference in 
morphology from the normal control up to E14.5.  
In normal mice, marrow elements were observed in the central area in 10/13 (77%) of 
normal tibia by E15.5, when the POC and bone collar are first observed. The marrow cavity 
and central bone elements continued to expand until E18.5 when the POC was fully 
developed (Figure 3.3A, E18.5). Flattened chondrocytes appeared at E15.5, and the 
columnar structure of proliferating and hypertrophic chondrocytes were clearly observed by 
E18.5 in the growth plate (Figure 3.3C). In contrast, formation of the primary centre of 
ossification was delayed in approximately 67% of MPS VII tibiae (deposition of marrow 
cavity observed in 4 out of 12 MPS VII mice, while hypertrophic chondrocytes still present 
in the diaphysis of 8 out of 12 MPS VII mice) at E15.5 (Figure. 3.3A). The morphology of 
chondrocytes in the growth plate were similar to the normal controls at this stage (Figure. 
3.3C). A marrow cavity containing bone elements was observed in all MPS VII tibiae at 
E16.5 (Figure 3.3A), suggesting formation of the POC in prenatal MPS VII tibiae appeared 
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one day later than the normal controls. Flattened proliferating chondrocytes and enlarged 
hypertrophic chondrocytes with poor columnar arrangement were observed in MPS VII 
epiphysis at E18.5 (Figure 3.3C). While the POC continued to expand accompanied by 
longitudinal bone growth in both normal and MPS VII tibia during the remainder of the 
embryonic and early postnatal period, the MPS VII metaphysis was consistently shorter 
than normal mice. 
In the normal tibia, hypertrophic chondrocytes were observed in the future SOC at P7. Bone 
marrow cells appeared in the proximal epiphyseal cartilaginous region of normal tibia by 
P10 (Figure. 3.4A). Hypertrophic chondrocytes were also observed in the MPS VII tibiae at 
P7 but a distinguishable SOC was not observed at P10 (Figure 3.4A). A large invasion of 
bone marrow cells into the SOC region occurred in normal tibial epiphyses by P11. In 
contrast, formation of SOC was delayed in approximately 83% of MPS VII mice (observed 
in 5 out of 6 MPS VII mice). Formation of the SOC did initiate in 17% of MPS VII mice at 
this age and all MPS VII mice showed evidence of bone deposition in the SOC by P12 
(Figure 3.4A). Expansion of the SOC in MPS VII mice was less than that of normal at P14 
and 2 months of age (Figure 3.4A) and occupied 10.0±2.7% and 42.0±3.0% of the total 
epiphyseal area respectively (Figure 3.4B). Despite the delay, there was a change of the 
shape of the SOC from spherical to hemispherical in both normal and MPS VII epiphysis 
as mice aged. 
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Figure 3.3: Formation of the POC and growth plate in the embryo. Sagittal sections of 
the tibial POC were stained with safranin O/fast green and an image taken at the mid-
anlage/diaphyseal region (A). At E15.5 an example of an MPS VII tibia with a POC 
(E15.5(i)) and an MPS VII tibia with no evidence of POC formation (E15.5 (ii)) is shown. 
A higher magnification of the boxed area at E12.5 and E13.5 is shown in (B). Safranin 
O/fast green stained sections showing the proximal tibial growth plate (C). Scale bar=100 
µm in A and C. Scale bar = 20 µm in B. P= perichondrium, HPC = hypertrophic 
chondrocytes, BC = bone collar, PO = periosteum, PC = proliferative chondrocytes. Black 
arrow = bone marrow, oval arrow = blood vessel, arrow head = bone. The number of animals 
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Figure 3.4 Formation of the SOC and expansion of the growth plate in the postnatal 
tibia. Sagittal sections through the proximal tibial epiphysis were stained with safranin 
O/fast green and showed the formation of the SOC (A). Scale bar=100 µm. At P11, two 
phenotypes of MPS VII epiphysis were shown, representing the absence of the SOC 
(middle) and presence of the SOC (right) in epiphysis of MPS VII mice. Black arrow, bone 
marrow. Oval arrow, blood vessel. Arrow head, bone. Quantitative analysis of the area of 
the proximal tibial epiphysis occupied by SOC (C). Mean ± S.E.M. The number of animals 
used was listed in Table B2 and B4 of Appendix B.  
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3.3.2 MPS VII mice have lengthened RZ and HZ in the tibia growth plate 
Histological analyses of MPS proximal tibia sections (Chapter 2.3.2) revealed an abnormal 
growth plate in MPS VII mice (Figure 3.5A). The growth plate was enlarged, especially in 
the RZ, and columnar arrangement of the chondrocytes was disrupted in severe MPS VII 
(Gusmps/mps) mice. Attenuated MPS VII mice (GustmSly(L175F)) also displayed a thickened 
growth plate with a slightly disorganized structure, while MPS I tibial growth plate was 
comparable to normal mice. 
By P14 it was clear that the growth plate in MPS VII mice was abnormally enlarged with a 
larger RZ and HZ. While PZ chondrocytes lined up in long columns in the normal mice, 
MPS VII chondrocytes lost their columnar arrangement in the PZ (Figure. 3.5B). To further 
confirm the observed differences and gain a detailed understanding of the abnormalities in 
MPS VII growth plate morphology, growth plate zone height, the number of chondrocytes 
and lacunae size of the three distinct zones (the RZ, PZ and HZ) were quantified (Chapter 
2.3.3).  
Total growth plate height declined with age in both normal and MPS VII mice (Figure 
3.6A). However, total growth plate height in MPS VII mice was significantly higher from 
1 month of age onwards (p<0.05) than normal mice. Measurement of individual growth 
plate zone heights were carried out in mice of P14, 1 month and 2 months only, as individual 
zones were difficult to distinguish in older animals. A significant higher RZ height (p<0.05) 
was observed in MPS VII mice at all time points when compared to normal (Figure 3.6B). 
There were no statistically significant changes in the growth plate RZ height between 
different time points in the normal mice; however, the RZ height of growth plate 
significantly increased between 1 and 2 months in MPS VII mice (p<0.05). The heights of 
the PZ were unchanged from normal in MPS VII mice (Figure 3.6C). The PZ of the growth 
plate became thinner in both normal and MPS VII mice as they aged (p<0.05). MPS VII HZ 
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height was significantly lower than normal controls at P14, the same as normal at 1 months 
of age and significantly higher than normal at 2 months of age (p<0.05) (Figure 3.6D). 
While the height of the HZ of normal mice tibial growth plate significantly decreased with 
age (p<0.05), no significant changes in MPS VII growth plate HZ height were observed 
between different time points.  
3.3.3 Enlarged chondrocytes due to lysosomal storage 
The horizontal diameter of lacunae in the growth plate were measured to compare the size 
of normal and MPS VII chondrocytes (Chapter 2.3.3). MPS VII chondrocytes were 
significantly larger than normal chondrocytes (Figure 3.7A) in the RZ at P14, 1 month and 
2 months of age. PZ chondrocytes were elongated only at 1 month of age in MPS VII growth 
plate (Figure 3.7B). HZ chondrocytes in MPS VII growth plate enlarged horizontally from 
1 month of age onwards (Figure 3.7C). TEM observations (Chapter 2.4) clearly revealed 
enlarged and vacuolated chondrocytes in the RZ of MPS VII mice (Figure 3.7D). MPS VII 
PZ chondrocytes had condensed nuclei, with accumulated storage of GAGs inside the cells. 
Similar vacuolated structure was observed in the HZ of MPS VII growth plate. 
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Figure 3.5 Histology of the growth plate in normal and MPS mice. Sagittal sections 
through (A) the proximal tibial growth plate of normal, MPS VII (Gusmps/mps), MPS VII 
mice (Gustm(L175F)Sly)  and MPS I at P14. (B) the proximal tibial epiphysis showed the 
development of the growth plate in normal and MPS VII mice from P14 to 6 months. 
Sections were stained with safranin O/fast green. The number of animals used were listed 


































60 | P a g e  
 
 
Figure 3.6 Histomorphometric analysis of the growth plate in normal and MPS VII 
mice. Quantitative analyses of (A) total height, (B) resting zone height, (C) proliferative 
zone height, and (D) hypertrophic zone height of the growth plate in normal and MPS VII 
mice from P14 to 2 months. Mean ± S.E.M. The number of animals used were listed in 
Table B3 of Appendix B. 
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Figure 3.7 Chondrocyte size and GAG storage in the growth plate. Chondrocyte size in 
the (A) resting zone (RZ), (B) proliferative zone (PZ) and (C) hypertrophic zone (HZ) of 
the growth plate in 2 months old normal and MPS VII mice. Results are expressed as the 
mean ± S.E.M. The number of animals used were listed in Table B3 of Appendix B. TEM 
(D) of chondrocytes of RZ, PZ and HZ of P14 normal and MPS VII growth plate. Yellow 
arrow, lysosomal storage. Scale bar = 5 µm.  
* denotes significant difference between normal and MPS VII (p<0.05, Two-way 
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3.4 Decreased number of PZ chondrocytes is not due to apoptosis in the MPS VII 
growth plate 
In the RZ, no difference in the cell number (Chapter 2.3.3) was observed between normal 
and MPS VII mice at P14 and 1 month of age (Figure 3.8A). However, at 2 months of age, 
a significant increase in the number of cells per mm2 was observed in MPS VII mice 
(2471±118 cells/mm2) compared to normal mice (1600±157 cells/mm2; p<0.05). The 
number of chondrocytes in the PZ of normal mice tended to be consistent with ages, while 
cell number in the proliferating zone of MPS VII mice decreased with age and was 
significantly reduced compared to normal (Figure 3.8B; p<0.05). The number of cells in the 
HZ of normal mice increased with age (Figure 3.8C). More hypertrophic cells were 
observed in MPS VII mice (2623±72 cells/mm2) at P14 when compared to normal mice 
(2255±55 cells/mm2; p<0.05), while MPS VII mice had fewer hypertrophic cells (2152±85 
cells/mm2) at 2 months of age when compared to normal mice (2935±93 cells/mm2; p<0.05).  
To determine whether the changes in cell number in the growth plate of MPS VII mice are 
the result of increased apoptosis, the expression of apoptosis associated genes was evaluated 
by real-time PCR analysis (Chapter 2.9). Bcl2 expression was also elevated significantly in 
MPS VII growth plate; however, the ratio of Bcl/Bax was not significantly different from 
normal (Figure 3.9A). Expression of FasL was absent from both normal and MPS VII 
growth plate, while expression of FasR was slightly increased without reaching statistical 
significance. Casp3 expression was significantly increased in the whole growth plate of 
MPS VII mice (Figure 3.9B, p<0.05), which was confirmed by increased immunostaining 
of uncleaved Caspase3 in the MPS VII growth plate when compared to normal mice (Figure 
3.9C). However, the expression of cleaved/activated Caspase 3 was absent from both normal 
and MPS VII growth plate, suggesting that growth plate chondrocytes was were not 
undergoing apoptosis.  
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Figure 3.8 The number of chondrocytes in the growth plate of normal and MPS VII 
mice. The number of chondrocytes in the (A) resting zone, (B) proliferative zone and (C) 
hypertrophic zone of normal and MPS VII mice aged P14 to 2 months. Results are expressed 
as the mean ± S.E.M. The number of animals used were listed in Table B3 of Appendix B. 
* denotes significant difference between normal and MPS VII (p<0.05, Two-way ANOVA, 
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Figure 3.9 Apoptosis in the growth plate of normal and MPS VII mice. (A) Gene 
expression of Caspase 3, Bcl2, Bax and FasR in P14 MPS VII growth plate was expressed 
as the fold change compared to normal growth plate. Gene expression was normalized to 
cyclophilin A and the fold change in the expression of genes from MPS VII growth plate 
compared to normal growth plate was calculated using the ΔΔCt method of n=5 replicates. 
(B) Ratio of Bcl2/Bax gene expression in P14 normal and MPS VII growth plate. (C) 
Immunohistochemistry of Caspase 3 and cleaved Caspase 3 was determined in P14 normal 
and MPS VII proximal tibia. Results are expressed as the mean ± S.E.M. of n=3 replicates. 
Bar scale = 20 µm. 
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3.5  Discussion 
Bone elongation is severely compromised in patients with MPS I (Neufeld & Muenzer 2001; 
Rozdzynska-Swiatkowska et al. 2015), II (Rozdzynska-Swiatkowska et al. 2015), IVA 
(Montaño et al. 2008), IVB (Kubaski et al. 2016), VI (Neufeld & Muenzer 2001) and VII 
(Montano et al. 2016; Sly et al. 1973)). Growth retardation of MPS patients starts in early 
childhood and becomes progressively worse with age (Montaño et al. 2008; Neufeld & 
Muenzer 2001) as GAG accumulates in connective and skeletal tissues. GAG storage is 
observed in chondrocytes and osteoblasts of foetal MPS VII mice at 15 days post cotium 
(dpc) and 18 (dpc) respectively (Vogler et al. 2005). However, it is unknown how this early 
storage impacts cartilage and bone development. The purpose of this chapter was to 
determine which murine model best reproduces the reduced bone length phenotype of 
human MPS and to use this model to characterise tibial development from the foetus to 
skeletal maturity.  
Initial evaluation of long bone and vertebral lengths at maturity showed that bone length in 
mouse models of MPS IIIA, MPS VII (Gusmps/mps), MPS VII (Gustm (L175F)Sly) and MPS IX 
paralleled the corresponding human disorders (Fischer et al. 1998; Imundo et al. 2011; 
Natowicz et al. 1996; Neufeld & Muenzer 2001). Much like humans with MPS IIIA or MPS 
IX and other MPS IIIA animal models (Fischer et al. 1998; Imundo et al. 2011; Natowicz 
et al. 1996; Neufeld & Muenzer 2001), the lengths of bones in murine MPS IIIA and MPS 
IX were not pronouncedly different to normal mice at maturity. Long bone and vertebral 
growth was most severely affected in the severe MPS VII (Gusmps/mps) mouse model, which 
exhibited shortened bones from a very young age. Bone length discrepancies in murine 
Gusmps/mps are consistent with human (Montano et al. 2016; Sly et al. 1973), canine (Herati 
et al. 2008; Smith, LJ et al. 2012) and feline MPS VII (Fyfe et al. 1999; Wang, P et al. 2015). 
Mice with the attenuated form of MPS VII (Gustm(L175F)Sly) also displayed significantly 
66 | P a g e  
 
decreased lengths of femur and tibia (but not vertebral) bones, but the discrepancy compared 
to normal mice was less than that observed in the Gusmps/mps strain. Unlike the Gusmps/mps 
strain, femur lengths were not significantly different to normal mice at younger ages in the 
Gustm(L175F)Sly  strain. The L175F mutation in murine MPS VII is analogous to the L176F 
mutation that affecting 20% of MPS VII patients who display a mild phenotype (Tomatsu 
et al. 2002; Wu, BM et al. 1994). In contrast, bone length in the murine MPS I model did 
not represent human MPS I (Neufeld & Muenzer 2001; Silveri et al. 1991). Only the femur 
was modestly shortened in murine MPS I at older ages (3 and 6 months of age). Tibia lengths 
were relatively normal at all ages. These are in agreement with previous study that long 
bone lengths (tibia and humerus) in MPS I mice at 8 months of age were relatively normal, 
except for a modest reduction in femur lengths in females (Liu, Y et al. 2005). Bone lengths 
of canine MPS I (Herati et al. 2008) are not significantly different to normal controls, and 
feline MPS I models (Haskins et al. 1983) had no obvious dwarfism. 
The discrepancy of bone shortening between the three mouse models (MPS VII (Gusmps/mps), 
MPS VII (Gustm (L175FSly)) and MPS I) may be attributed to the fact that growth plate is much 
more impaired in severe MPS VII mice than the others (Figure 3.5A). The severity of growth 
plate dysfunction in MPS is probably affected by residual enzyme activity. GAG has been 
shown to dramatically accumulate due to the deficiency of β-glucuronidase in the growth 
plate of MPS VII animals (Metcalf et al. 2009). The Gusmps/mps mice had 0.34-1% normal β-
glucuronidase activity (Birkenmeier et al. 1989; Macsai et al. 2012; Vogler et al. 1990). 
This theory can be supported by observations in other MPS animal models. MPS VII dogs 
and cats, which have severely shortened bones, have approximately 0.2% and 0% of normal 
β-glucuronidase activity, respectively (Schuchman et al. 1989; Wang, P et al. 2015). As the 
Gustm(L175F)Sly  mice have 1% normal β-glucuronidase activity (Derrick-Roberts et al. 2014; 
Tomatsu et al. 2002), this lead to less accumulated GAGs, resulting in a less severely 
disorganized growth plate (Figure 3.5A) and less shortened long bones (Figure 3.2B & E). 
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In contrast, the enzyme activity of α-L-iduronidase in MPS I dogs and cats, whose bone 
length are relatively normal, were approximately 4% and 2.4% of normal, respectively, 
compared to <1% in human MPS I (Bunge et al. 1998; Herati et al. 2008; Oussoren et al. 
2013; Traas et al. 2007). Therefore, it is likely that MPS VII animals have more severely 
shortened bone growth than MPS I animals because MPS VII animals have less enzyme 
activity. However, MPS I mice had approximately 0.2% of normal α-L-iduronidase enzyme 
activity (Clarke, LA et al. 1997; Liu, Y et al. 2005), and with this residual enzyme activity 
it  would be expected to display a bone length phenotype closer to human MPS I. At present, 
there is no explanation for the discrepancy in bone length phenotype between murine and 
human MPS I. 
Among the three mouse models with bone length deficits, the reduction in femur length 
tended to be more severe that in the tibia, especially for MPS I whose femur was 
significantly shortened while the tibia was relatively normal at maturity. During pregnancy 
the femur growth rate is higher than that in the tibia; while after birth the tibia has the highest 
grow rate compared to other limbs in mice (Patton & Kaufman 1995). The ‘overtake’ nature 
of tibia growth may therefore contribute to the observed difference of bone shortening 
between femur and tibia.  
The naturally occurring MPS VII (Gusmps/mps) mouse model exhibited the most severe bone 
shortening phenotype, which replicates the pathology observed in human patients (Neufeld 
& Muenzer 2001; Sly et al. 1973), making it an ideal model for investigating the pathology 
of bone defects in MPS. The results of this chapter are consistent with a single study of bone 
shortening in MPS VII mice (Metcalf et al. 2009), and extends this observation to a 
comparison of the time course of EO progression in MPS VII mice to normal mice. 
Histological analyses suggested that the conversion from cartilage to bone during EO was 
delayed in MPS VII mice. The time of first appearance of POC in the normal tibia was at 
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E15.5, which is consistent with previous studies (Dao et al. 2012; Patton & Kaufman 1995; 
Wang, Y et al. 2015). It is notable that MPS VII hindlimbs showed some variations in the 
initiation of POC from one embryo to another. Initiation of the POC was not observed in 
approximately 67% of MPS VII mice at E15.5 but was observed in all MPS VII mice at 
E16.6, suggesting that MPS VII mice have a slower development of the POC than that of 
normal mice.  
The SOC of normal mouse tibia formed at around P10. In MPS VII mice, the development 
of the SOC was delayed by approximately two days. Prenatally hypertrophic chondrocytes 
trigger invasion of blood vessels, bone cells and bone marrow cells from the perichondrium 
to direct matrix mineralization and differentiation of perichondrial cells to osteoblasts 
(Carlevaro, M. F. et al. 2000; Long 2012; Takahara et al. 2004). Postnatal formation of the 
SOC is similar to the formation of the POC, but its establishment involves formation of 
cartilage canals (Burkus, Ganey & Ogden 1993; Wang, Y et al. 2015). In this chapter, the 
delayed POC and SOC appearance in MPS VII suggested that there was a defect during the 
conversion from cartilage to bone, which maintained the chondrocytes in a hypertrophic 
state, thus possibly delaying the degradation of cartilage matrix and invasion of blood 
vessels.  
Growth plate height in normal mice decreases with age as bones grow in length. However, 
total growth plate height in MPS VII mice was significantly higher than normal from 1 
month of age onwards. Although decrease of the growth plate height still occurred in MPS 
VII mice, the process appeared to be slower than normal, leaving a thicker than normal 
growth plate at maturity, which was consistent with previous observation of thickened 
growth plates in MPS VII feline and MPS I murine model (Nuttall et al. 1999; Russell et al. 
1998). The thickened growth plate is possibly the result of an impaired conversion of 
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chondrocytes from resting to proliferation and from hypertrophic to bone, as the RZ and HZ 
of MPS VII were greatly enlarged in the growth plate. 
The RZ in MPS VII growth plate was significantly enlarged, accompanied with elevated 
number, size and density of chondrocytes. Consistently, increased zone height and enlarged 
cells were also observed in the RZ of MPS VI cat tibia growth plate (Abreu et al. 1995; 
Nuttall et al. 1999). These anomalies suggested the transition of chondrocytes from the 
resting to the proliferative stage (Abad et al. 2002) would be limited. TEM observations 
suggested that the enlarged chondrocytes in the RZ was due to accumulation of storage 
inside the cells (Figure 3.7D). However, it is still not clear whether accumulation of storage 
in the MPS VII RZ chondrocytes prevent them from progressing to proliferation. 
Chondrocyte proliferation and hypertrophy both contribute to linear bone growth. 
Decreased or delayed chondrocyte proliferation in the growth plate therefore may lead to 
shortened bones. In MPS VII mice, the PZ height and size of PZ chondrocytes were not 
significantly different to normal mice; however, a marked decrease in the number of cells 
was observed, which was consistent with previous findings that the number of chondrocytes 
per column in the PZ of 3 weeks old MPS VII mice decreased to approximately 60% of 
normal (Metcalf et al. 2009). Early cell death caused by increased apoptotic activity may 
cause the decrease in the number of proliferative chondrocytes. Apoptosis in the cartilage 
is induced by activation of Caspase 3 (Matsuo et al. 2001). The balance between Bax and 
Bcl2 levels and the FasL/FasR system can also determine the fate of cells in cartilage (Ju et 
al. 1995; Oltvai, Milliman & Korsmeyer 1993). These results suggested that the decrease in 
MPS VII PZ chondrocytes is not due to increased apoptosis but is due to a decreased 
proliferation rate in the affected growth plate (Metcalf et al. 2009).  
At the end of chondrocyte hypertrophy, chondrocytes progress to cell death and the matrix 
becomes mineralized and converted into bone. In MPS VII mice, HZ height remained 
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constant over the time points, while it decreased with age in normal mice. MPS VII HZ 
chondrocytes had increased chondrocyte size but decreased cell number. The constant zone 
height observed in the HZ suggested that MPS VII mice tend to maintain the growth plate 
chondrocytes in the hypertrophic state, delaying the maturation of chondrocyte and 
progression into bone. These findings are consistent with previous observations in MPS VI 
cats and rats that the HZ height and chondrocyte size were significantly increased as 
compared to age-matched normal (Abreu et al. 1995; Nuttall et al. 1999) and was 
accompanied by a decrease in the HZ cell number (Simonaro et al. 2005). The decreased 
number of chondrocytes undergoing hypertrophy in MPS VII growth plate may also be 
attributed to a delay in the transition of chondrocytes from proliferating to hypertrophic state 
in MPS.  
In summary, this chapter has demonstrated that murine MPS VII mouse models, especially 
the severe strain (Gusmps/mps), provide good representations of short stature similar to 
patients with MPS. Findings of morphological abnormalities in MPS VII growth plate 
suggested a progressive defect in bone development that is caused by the delay of the 
programmed EO in the growth plate. The transition steps includes (i) the initiation of 
proliferation, which requires strictly regulated cell cycle progression (ii) cessation of 
proliferation which is mediated through the withdrawal from the cell cycle accompanied by 
hypertrophic differentiation, and (iii) blood vessel invasion preceding bone deposition. 
Programmed proliferation and hypertrophic differentiation of chondrocytes require strictly 
regulated cell cycle progression and the guidance of signalling pathways involving 
endocrine, and paracrine/autocrine factors. Therefore, the delay observed during the 
transition steps of EO in MPS VII growth plate could be due to disruptions of the cell cycle 
progression and/or dysfunction of signalling pathways. In the next chapter, cell cycle 
progression of MPS VII chondrocytes in the growth plate will be discussed in detail.   











4 Normal cell cycle progression is disrupted in 
MPS VII growth plate chondrocytes 
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4.1 Introduction 
Growth of endochondral bone proceeds through a strict temporal and spatial sequence of 
events as growth plate chondrocytes divide, synthesize matrix, and undergo hypertrophic 
differentiate in order to create an environment suitable for new bone deposition (Byers et 
al. 1992; Byers et al. 1997; Gibson & Flint 1985). Central to this process is the synchronized 
entry into and exit out of the cell cycle by growth plate chondrocytes in order to initiate 
proliferation and subsequent hypertrophic differentiation. The time chondrocytes spend on 
completing a cell cycle varies in growth plates growing at different rates, leading to the 
differential growth of long bones (Wilsman et al. 1996). Chondrocytes in growth plates that 
grow slowly spend a longer time in the G1 phase of the cell cycle. DNA replication, or S 
phase, predominately occurs in the PZ of the growth plate. Chondrocytes in the PZ pass 
through the G2 phase and progress through the M phase rapidly for division. Chondrocytes 
positioned proximally in a column seem to have a higher probability of division than those 
positioned distally (Farnum & Wilsman 1993). Transition of proliferative chondrocytes to 
terminal differentiation occurs predominately in the pre-HZ. The decisions of whether a 
chondrocytes progress through the cell cycle to divide again or alternatively exit the cell 
cycle are made during the G1 phase (Zetterberg & Larsson 1985). Upregulation of CKIs 
ensures chondrocytes withdrawal from the cell cycle during this step. Therefore, the 
appropriate level and timing of expression of proteins including cyclins, CDKs, E2F, pocket 
proteins and CKIs in the chondrocytes are essential for normal endochondral bone growth.  
Although several studies have shown disruption of the cell cycle genes that govern transition 
from G1 to S phase result in shortened bones (Cobrinik et al. 1996; Lee, MH et al. 1996; 
Zhang, P et al. 1997), the status of cell cycle progression in MPS growth plate has not been 
investigated. This chapter therefore aimed to investigate the regulation of EO through cell 
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cycle progression in MPS VII mice. The hypothesis of this chapter is that the synchronised 
entry and exit from the cell cycle are disrupted in MPS VII growth plate.  
4.2 More MPS VII chondrocytes were in the G1 phase and committed to enter S 
phase  
Cells throughout the normal growth plate were positive for Ki67 antigen, a marker for all 
active phases of the cell cycle (Figure 4.1A). The number of cells positive for Ki67 in the 
MPS VII growth plate was greater than normal in the PZ (Figure. 4.1B) (175.0±13.7% of 
normal, p<0.05) and HZ (251.5±36.1% of normal, p<0.05), respectively, suggesting more 
MPS VII chondrocytes were in the cell cycle.  
Cells positive for Cyclin D1 were observed predominantly in the early (upper cells in the 
columns) PZ of normal growth plate and to a lesser extent in the RZ, while HZ chondrocytes 
were negative for Cyclin D1 (Figure 4.1C). In MPS VII, higher but not statistically 
significant levels of Cyclin D1 staining was observed in the RZ and PZ of the growth plate. 
In contrast to normal, the number of cells stained positive for Cyclin D1 were also observed 
in the late (lower cells in the columns) PZ and HZ of MPS VII growth plate. In the HZ, 
6.8±1.6% of MPS VII chondrocytes were positive for Cyclin D1 (Figure. 4.1D, p<0.05), 
indicating these cells were still in G1 phase.  
Cells positive for pocket protein phos-pRb were mainly observed in the normal RZ and PZ, 
with limited positive staining observed in the HZ (Figure. 4.2A&B, p<0.05). While in MPS 
VII, the number of chondrocytes positive for phos-pRb was increased in the HZ (Figure 
4.2B, 387.1±46.9% of normal, p<0.05), suggesting that dephosphorylation of pocket 
proteins for cell cycle withdrawal was limited in MPS VII HZ chondrocytes. Cells positive 
for phso-p130, were observed throughout the normal growth plate (Figure. 4.2C). In MPS 
VII growth plate, the number of cells positive for phos-p130 in the three zones was not 
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significantly different to that of normal (Figure. 4.2 C&D). The expression of 
phosphorylated p107 was not observed in the growth plate region of either normal or MPS 
VII mice (data not shown).  
E2F1, the activator E2F protein essential for G1 to S phase transition, was mainly observed 
in the RZ and early PZ chondrocytes of normal growth plate (Figure. 4.3A&B, p<0.05), and 
to a significantly lesser extent by the HZ chondrocytes, especially in the pre-HZ region. 
However, the number of cells stained positive for E2F1 in the MPS VII growth plate were 
significantly increased to 123.8±14.2%, 170.3±13.0%, 279.6±9.1% of normal in the RZ, PZ 
and HZ, respectively (Figure. 4.3B, p<0.05). The staining of E2F1 in the MPS VII growth 
plate was not limited to early PZ chondrocytes and pre-HZ chondrocytes but was also 
observed in late PZ and late HZ chondrocytes (Figure 4.3A). 
E2F4, the most abundant transcription repressor of the E2F family, was predominantly 
expressed by the PZ chondrocytes of normal growth plate, and to a lesser extent by the RZ 
and HZ cells (Figure 4.3C). In MPS VII growth plate, the number of cells stained positive 
for E2F4 were significantly decreased to 13.8±7.1% of normal growth plate and 8.8±4.5% 
of normal growth plate in the RZ and PZ, respectively (Figure 4.3 D). 
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Figure 4.1 Immunohistochemical staining of P14 growth plate for Ki67 and CyclinD1. 
IHC and quantification of cells positive for Ki67 (A) and CyclinD1 (B). Results were 
presented as the percentage of positive cells in the RZ, PZ and HZ, mean ± S.E.M. of n=3 
replicates. Scale bar=20μm.  
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Figure 4.2 Immunohistochemical staining of P14 growth plate for pocket proteins. IHC 
and quantification of cells positive for phosphorylated pRb (phos-pRb) (A) and 
phosphorylated p130 (phos-p130) (B). Results were presented as the percentage of positive 
cells in the RZ, PZ and HZ, mean ± S.E.M. of n=3 replicates. Scale bar=20μm.  
*denotes significant differences between normal and MPS VII mice.  
# denotes significant differences between zones of normal growth plate (p<0.05, Two-way 
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Figure 4.3 Immunohistochemical staining of P14 growth plate for E2Fs. IHC and 
quantification of cells positive for E2F1 (A) and E2F4 (B). Results were presented as the 
percentage of positive cells in the RZ, PZ and HZ, mean ± S.E.M. of n=3 replicates. Scale 
bar=20μm.  
*denotes significant differences between normal and MPS VII mice.  
# denotes significant differences between zones of normal growth plate (p<0.05, Two-way 
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4.3 Fewer MPS VII chondrocytes progressed to M phase 
Normal PZ chondrocytes were positive for phos-hisH3, a marker of cells undergoing mitosis 
(Figure 4.4A). The number of chondrocytes staining for phos-hisH3 decreased to 
52.4±14.9% of normal in MPS VII PZ (Figure 4.4B, p<0.05). Neither chondrocytes of 
normal nor MPS VII growth plate stained positive for phisH3 in the HZ (Figure 4.4A). 
Staining of CyclinB1 was observed in both normal and MPS VII chondrocytes in all three 
zones of the growth plate (Figure 4.4C). The number of MPS VII chondrocytes stained 
positive for CyclinB1 was not significantly different compared to that of normal (Figure 
4.4D).  
Figure 4.4 Immunohistochemical staining of P14 growth plate for mitosis markers. 
IHC and quantification of cells positive for phosphorylated hisH3 (phos-hisH3) (A) and 
CyclinB1 (B). Results were presented as the percentage of positive cells in the RZ, PZ and 
HZ, mean ± S.E.M. of n=5 replicates for phos-hisH3 and n=3 replicates for CyclinB1. Scale 
bar=20μm.  
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4.4 Fewer MPS VII chondrocytes progressed to cell cycle withdrawal  
Expression of cyclin/CDK inhibitor p57kip2, a marker for terminally differentiated cells 
destined to exit the cell cycle, was observed predominately in the HZ of normal growth plate 
(Figure 4.5A & B, p<0.05), while the number of HZ cells positive for p57kip2 was 
significantly reduced to 50.9±10.9% of normal in MPS VII growth plate (Figure 4.5A & B). 
 
 
Figure 4.5 Immunohistochemical staining of P14 growth plate for p57kip2. 
Quantification of cells positive for p57kip2 were presented as the percentage of positive cells 
in the RZ, PZ and HZ, mean ± S.E.M. of n=3 replicates. Scale bar=20μm.  
*denotes significant differences between normal and MPS VII mice.  
# denotes significant differences between zones of normal growth plate (p<0.05, Two-way 
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4.5 Discussion 
Cell cycle regulation is essential for chondrocyte proliferation and hypertrophy, in which 
the entry of chondrocytes into M phase results in mitotic division and the withdrawal of 
chondrocytes from the cell cycle allows the transition to hypertrophic phenotype. In this 
chapter, the expression of multiple markers that represent different phases of the cell cycle 
and several regulators that control cell cycle progression in the growth plate region of 
normal and MPS VII mice were analyzed.  
Under normal circumstances, most chondrocytes in the PZ undergo G1/S transition, DNA 
replication and mitotic division. Cells positive for Ki67, a nuclear protein, are considered to 
have entered the cell cycle. A higher percentage of chondrocytes in the PZ of MPS VII mice 
were positive for Ki67, suggesting more MPS VII chondrocytes were in the cell cycle. The 
balance of the activator and repressor E2F proteins regulate G1/S phase transition of the cell 
cycle. While free E2F1 promotes transcription of genes required for DNA replication 
(Gaubatz et al. 2000), nuclear E2F4/pocket protein (pRb, p130 or p107) complexes 
(Moberg, Starz & Lees 1996) inhibit this process. The elevated expression of E2F1 and 
reduced expression of E2F4 in the PZ of MPS VII growth plate therefore suggest that more 
MPS VII chondrocytes in the PZ were in the G1 phase and had committed to enter S phase. 
Since the differential proliferation rate of the growth plates is attributed to the differences 
in the time that PZ chondrocytes of the growth plates spend in the G1 phase (Wilsman et al. 
1996), the longer time of MPS VII chondrocytes stayed in the G1 phase would lead to slower 
proliferation rate.  
Furthermore, a decrease in the number of PZ chondrocytes that expressed the M phase 
marker phos-hisH3 was observed in MPS VII mice, indicating that fewer MPS VII 
chondrocytes progressed to mitotic division. Comparison of CyclinB1 expression, which is 
highly expressed during the G2 and early M phase between normal and MPS VII growth 
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plate, suggested that the failure of MPS VII chondrocytes in progressing to mitotic division 
was not caused by deficiency of CyclinB1 protein. Clearly, MPS VII PZ chondrocytes 
entered the cell cycle and had the potential to replicate DNA, but they failed to progress to 
mitotic division. As a result, the number of chondrocytes was reduced in PZ of MPS VII 
growth plate (Figure 3.8B). A previous study (Metcalf et al. 2009) showed a significantly 
reduced rate of proliferation in 3 weeks old MPS VII mice using BrdU incorporation. As 
BrdU is incorporated into the newly synthesized DNA during S phase, reduction in BrdU 
staining in the PZ suggested that fewer MPS VII chondrocytes were cable of progressing to 
DNA replication. The observation of elevated E2F1 expression in the PZ indicated a 
prolonged status of MPS VII chondrocytes at the G1 phase (Figure 4.3), while the mitotic 
division (M phase) (Figure 4.4A) were inhibited. These findings were similar to the response 
of cancer cells to S phase blockage using hydroxyurea or aphidicolin (Chen et al. 2013; Cho 
et al. 2005; Hung, Jamison & Schreiber 1996; Iwasaki, T et al. 1995), also suggesting that 
mid-late S phase, when DNA replicates, were inhibited in MPS VII PZ.  
Cell cycle withdrawal is required for hypertrophy and normal HZ chondrocytes are positive 
for p57kip2. The decision to progress to cell division or cell cycle withdrawal is made in the 
G1 phase (Zetterberg & Larsson 1985). Expression of Cyclin D1, which is a cartilage 
specific isoform of the D type cyclins, was limited to normal RZ and PZ chondrocytes 
(Long, Schipani, et al. 2001). Expression of this marker was not observed in the normal HZ, 
where cell cycle withdrawal is the major event. In contrast, MPS VII HZ chondrocytes 
continued to express Cyclin D1, but failed to express sufficient p57kip2, indicating that 
instead of exiting from the cell cycle, these MPS VII chondrocytes were still in the G1 
phase, which was also consistent with the observation of increased Ki67 staining in the HZ 
of MPS VII growth plate. This theory was further supported by elevated immunostaining of 
E2F1 and phos-pRb in MPS VII HZ. Downstream of Cyclin D1/CDK activity is the 
E2F/pRb complexes. During G0/G1 phase, where senescent chondrocytes exit the cell 
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cycle, upregulation of CKI (such as p57kip2) inhibits Cyclin D1/CDK activity, which lead to 
dephosphorylation of pRb. E2F1 is therefore blocked by activated pRb (unphosphorylated 
form) allowing for cell cycle withdrawal. The level of E2F1 and phos-pRb in normal 
chondrocytes was downregulated during the transition from the proliferative to hypertrophic 
phenotype. In contrast, persistence of these two proteins in the HZ of MPS VII growth plate 
suggested that although these chondrocytes were morphologically hypertrophic, they were 
more typical of proliferative cells, failing to undergo phenotypical changes for hypertrophic 
differentiation.  
A previous study has shown that overexpression of E2f1 disturbed the differentiation of 
chondrocytes in the HZ of the growth plate, which leads to delayed EO and shorter long 
bones in transgenic mice (Scheijen et al. 2003). Therefore, the lower number of HZ 
chondrocytes observed in MPS VII growth plate (Figure .8C) may be partially due to the 
persistence of E2F1. 
This chapter demonstrated for the first time that the pace of cell cycle progression in growth 
plate chondrocytes is disrupted in vivo. During the course of this thesis, a report was 
published showing MPS I and MPS II fibroblasts were less likely to progress to S and G2/M 
phase in vitro (Moskot et al. 2016), suggesting that disruption of the cell cycle progression 
may occur in more than one cell type in MPS. MPS VII is characterized by storage of HS, 
DS and CS. While the participation of DS in cell cycle regulation has not been reported, HS 
and CS can participate in cell cycle progression through interactions with BMP, WNT and 
IHH signalling pathways (Cortes, Baria & Schwartz 2009; De Leonardis et al. 2014; Manton 
et al. 2007; Zhang, F et al. 2007). 
By utilizing immunohistochemistry, the changes in cell cycle progress across the three 
distinct zones (the RZ, PZ and HZ) were clearly defined. However, the intracellular 
localization of the cell cycle regulators was not determined. The functions of E2F4 and 
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CyclinB1 are dependent on their localization within the cells. Nuclear translocation allows 
E2F4 to form complexes with pocket proteins, which block E2F1 activity (Lindeman et al. 
1997), and enables formation of CyclinB1-CDK1 complexes to activate downstream genes 
that are crucial for mitosis (Porter & Donoghue 2003). It is possible that proteins like E2F4 
and CyclinB1 are mis-localized within MPS VII chondrocytes as accumulation of GAG 
storage would alter cellular structure. Therefore, future examination of nuclear/cytoplasmic 
ratios of E2F4 and CyclinB1 in growth plate chondrocytes using Immuno-EM techniques 
may strengthen the understanding of the disturbance of cell cycle progression in the MPS 
VII growth plate.  
Collectively, in comparison to normal growth plate, more chondrocytes in the PZ stayed 
within the G1 phase of the cell cycle in the MPS VII growth plate. Although these cells 
were committed to enter S phase, fewer PZ cells were capable of progressing to DNA 
replication and subsequent mitotic division, and fewer HZ cells progressed to cell cycle 
withdrawal for terminal differentiation. This chapter demonstrated that progression through 
the G1 phase, mitotic division and cell cycle withdrawal were disrupted in growth plate 
chondrocytes of MPS VII mice, and thus pointed to potential targets for correcting growth 
plate dysfunctions, especially the reduced proliferation and hypertrophy of chondrocytes. 
Since the pace of cell cycle progression in the growth plate is strictly regulated by a complex 
network of endocrine and paracrine/autocrine factors, which therefore mediates the 
elongation of bones, in the next chapters, expression of such factors in MPS VII mice will 
be investigated to provide better understanding of the mechanism behind bone shortening 
in MPS.  
  











5 Endocrine factors involved in linear bone 
growth are dysregulated in MPS VII mice 
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5.1 Introduction 
EO is strictly regulated by a complex network of signalling pathways, controlling the pace 
and onset of chondrocyte proliferation and differentiation. These pathways include systemic 
factors that travels through the bloodstream, such as GH, T3, glucocorticoids, estrogen, 
testosterone, circulating IGF1 (Clarke, BL & Khosla 2009; Fernandez-Cancio et al. 2008; 
van der Eerden, Karperien & Wit 2003), as well as local factors like IHH and 
paracrine/autocrine IGF1. 
GH is the major hormone supporting longitudinal bone growth. GH is secreted by the 
pituitary gland in a pulsatile manner and primarily acts on the liver where it stimulates the 
production of IGF1 (Butler & Le Roith 2001), IGFALS and IGFBP, including IGFBP3, the 
most abundant form in the circulation (Baxter, Martin & Beniac 1989). This signalling 
pathway is mediated through the JAK2/STAT5 signalling cascade (Piwien-Pilipuk, Huo & 
Schwartz 2002; Teglund et al. 1998). Liver-derived IGF1 contributes to 75% of IGF1 in the 
circulating pool (Sjogren et al. 1999; Yakar et al. 1999). IGF is then delivered to bone and 
bound by bone/cartilage-derived IGFR1, regulating EO. GH is also delivered to bone and 
stimulate longitudinal bone growth through GHR (Gevers et al. 2002).  
T3 supports bone growth mainly by promoting chondrocyte hypertrophy (Robson et al. 
2000; Stevens et al. 2000). T3 stimulates IGF1 mRNA expression in chondrocytes (Ohlsson, 
Nilsson, Isaksson, Bentham, et al. 1992) and osteoblasts (Varga, Rumpler & Klaushofer 
1994) and increases IGF1 secretion from bone organ cultures (Lakatos et al. 1993). T3 also 
plays a critical role in IGF1 signalling and bone acquisition during the pre-pubertal period 
(Xing et al. 2012), suggesting that the action of T3 on bone growth is age-dependent.  
IHH is highly expressed by chondrocytes in the growth plate, but has also be found in lungs, 
liver, kidneys, gastrointestinal tract, ovarian and prostate (Lim et al. 2014; Liu, C et al. 2015; 
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Matz-Soja et al. 2014; McMahon, Ingham & Tabin 2003; Valentini et al. 1997). IHH 
regulates proliferation and the transition of chondrocytes to hypertrophy in conjunction with 
PTHrP (Koyama et al. 1996; Maeda et al. 2007; St-Jacques, Hammerschmidt & McMahon 
1999; Vortkamp et al. 1996). Although IHH is found in the circulation, there is little 
evidence suggesting a role for circulating IHH in bone growth. 
Lysosomal GAG storage has been observed in the pituitary gland, thyroid gland, 
hepatocytes and Kupffer cells in the liver of children with MPS II (Nagashima et al. 1976; 
Oda et al. 1988), suggesting endocrine function is likely impaired. Limited information is 
available on endocrine status in MPS patients. Gardner (2011) and Polgreen (2008) reported 
GH deficiency and GH insensitivity in some children with MPS IH post HSCT. 
Hypothyroidism has also been reported in one case of MPS IH/S patient (Mohanalakshmi, 
V. & S. 2014). Despite low IGF1 level, normal to high GH level has been reported in three 
siblings with MPS II, suggesting GH insensitivity (Toledo et al. 1991). Consistently, one 
single study found an increased expression of IGFBP1 and IGFBP2 in MPS VII mouse liver, 
indicating the bioavailability of IGF1 may be altered (Woloszynek et al. 2004).  
However, the mechanism behind these altered endocrine levels in MPS is not fully 
understood. The aim of this chapter was to characterize the regulation of bone growth at 
endocrine level in MPS VII mice. Based on the observation of lysosomal GAG storage in 
the pituitary gland, thyroid gland and liver cells of MPS patients, this chapter hypothesis 
that the level of GH, IGF1 and T3 is altered in the circulation of MPS VII mice. The level 
of GH, IGF1, IGFBP3, IGFALS, T3 and IHH was measured in the serum from normal and 
MPS VII mice at P14, 1, 2 and 6 months of age. Furthermore, GH-induced hepatic IGF1 
production and expression of major factors along the GH/IGF1 axis in the liver of normal 
and MPS VII mice were examined. 
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5.2 Serum analyses of endocrine factors in MPS VII mice 
5.2.1 Circulating GH level was not affected in young MPS VII mice, but ghrelin-
induced GH secretion was altered in MPS VII mice at 2 months of age. 
The circulating GH level was measured in serum samples from normal and MPS VII mice 
at P14 and 1 month of age (Chapter 2.2.1). The level of GH was not altered in MPS VII 
mice at P14 (101.7±21.1% of normal mouse level, Figure 5.1A). Although not statistically 
significant, GH level of MPS VII mice decreased to 58.7±16.6% of normal at 1 month of 
age (Figure 5.1A). 
It is difficult to monitor pulsatile GH secretion in mice, which requires frequent collection 
of blood due to constraints on their blood volume. Since ghrelin stimulates GH release from 
the pituitary gland (Kojima et al. 1999), exogenous ghrelin was used as an amplifier of GH 
pulsatility to investigate if GH secretion is affected by the progression of disease in MPS 
VII mice (Chapter 2.6). Administration of saline had no stimulatory effect on GH secretion 
in either normal or MPS VII mice at different ages. Administration of ghrelin greatly 
stimulated GH secretion in both normal and MPS VII mice at 1 and 4 months of age (Figure 
5.1B & D), and the GH level was not significantly different between normal and MPS VII 
mice 5 min and 15 min after ghrelin injection at both ages. At 2 months of age, 
administration of ghrelin stimulated GH secretion in normal mice 5 min and 15 min after 
injection (Figure 5.1C). In contrast, ghrelin-induced GH secretion in MPS VII mice was 
significantly reduced to that in normal mice, reaching only 26.8±11.5% and 22.7±10.1% of 
the normal levels (Figure 5.1C, p<0.05) 5 min and 15 min after injection, respectively. The 
levels of ghrelin-induced GH secretion in MPS VII mice at 2 months of age were not 
significantly different to those of age-matched mice with saline injection.  
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Figure 5.1 Ghrelin-induced GH secretion was decreased in young adult MPS VII mice. 
Circulating GH level (A) in normal and MPS VII mice at 14 days and 1 month of age (n=11 
replicates). The effect of ghrelin administration on GH secretion in normal and MPS VII 
mice at 1 month (B), 2 months (C) and 4 months (D) of age (n≥6 replicates for ghrelin (G), 
and n≥3 replicates for saline (S)). Results are presented as the mean±S.E.M. * denotes 
significant differences of ghrelin-induced GH level between normal and MPS VII mice, 
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5.2.2 Young MPS VII mice had decreased level of IGF1, IGFBP3 and IGFALS in the 
circulation 
IGF1, IGFBP3 and IGFALS levels in mouse serum at different ages were determined by 
ELISA as shown in Figure 5.2A, B & C. Serum IGF1 level in both normal and MPS VII 
mice raised during P14 to 2 months, and slightly decreased at 6 months of age. Young MPS 
VII mice (P14) showed a 58% reduction in circulating IGF1 (Table 5.1) 
The patterns of circulating IGFBP3 and IGFALS levels were similar to that of circulating 
IGF1. In both normal and MPS VII, IGFBP3 and IGFALS level increased from P14 
onwards, peaked at 2 months of age and decreased slightly at maturity. A 30% and a 60% 
reduction were observed on the circulating IGFBP3 level and IGFALS level respectively in 
MPS VII mice at P14 (Table 5.1). The molar ratio of IGF1: IGFBP3: IGFALS changed from 
1:3.6:4.4 in normal to 1:6.1:4.4 in MPS VII mice at P14, also suggesting the stability of the 
ternary complex was altered in the circulation of MPS VII mice. However, circulating IGF1, 
IGFBP3 and IGFALS levels in MPS VII mice were not significantly different to those of 
normal mice at 1, 2 or 6 months of age.  
 
Table 5.1 Circulating IGF1, IGFBP3 and IGFALS levels in MPS VII mice  
 Normal MPS VII 
IGF1 242.9±29.5 ng/ml
*
 102.2±11.3 ng/ml 
IGFBP3 3276.7±300.4 ng/ml
*
 2283.2±235.5 ng/ml 
IGFALS 9351.2±1215.7 ng/ml
*
 3737.5±773.5 ng/ml 
 
Circulating IGF1, IGFBP3 and IGFALS level in normal and MPS VII mice at P14. 
Results are presented as the mean ± S.E.M of n=9 replicates. 
* denotes significant difference between normal and MPS VII mice (p<0.05, 
Student’s t-test). 
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Serum IGF1 level was also measured in attenuated MPS VII (Gustm(L175F)Sly strain), which 
displayed a mild bone shortening (Chapter 3.2, Figure 3.1 & 3.2), and MPS IIIA mice, which 
has normal bone length (Chapter 3.2, Figure 3.1) (Figure 5.2D). Interestingly, attenuated 
MPS VII (Gustm(L175F)Sly strain) mice had a significantly higher serum IGF1 level than that 
of severe MPS VII mice; however, this level (63.2±7.5% of normal mice) was still 
significantly decreased as compared to the normal and MPS IIIA mice. In contrast, MPS 
IIIA mice had serum IGF1 level similar to that of normal mice (121.9±26.3% of normal 
mice), which was significantly higher than that of severe MPS VII mice. These findings 
indicated a correlation between bone shortening and the circulating IGF1 level in MPS mice.  
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Figure 5.2 Circulating IGF1, IGFBP3 and IGFALS levels were significantly decreased 
in P14 MPS VII mice. Circulating IGF1 (A), IGFBP3 (B) and IGFALS (C) level in normal 
and MPS VII mice at P14, 1 month, 2 months and 6 months of age (n≥9 replicates). (D) 
Comparison of circulating IGF1 level in normal, severe MPS VII (Gus
mps/mps
), attenuated 
MPS VII (L175F represents Gus
tm(L175F)Sly
) and MPS IIIA mice at P14 (n≥8 replicates). 
Results are presented as the mean ± S.E.M.  
* denotes significant difference between normal and MPS mice.  
# denotes significant difference between severe MPS VII and L175F or MPS IIIA mice.  
## denotes significant difference between L175F and MPS IIIA mice.  
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5.2.3 Circulating T3 level was not affected in MPS VII mice  
Circulating T3 level was constant in both normal and MPS VII mice from 14 days to 6 
months of age (Figure 5.3A). The level of circulating T3 in MPS VII mice was not 
significantly different to those of normal mice at P14 (114.2±15.4% of normal), 1 month 
(95.3±14.3% of normal), 2 months (111.9±6.0% of normal) and 6 months of age 
(85.5±7.3% of normal). 
 
Figure 5.3 Circulating T3 and IHH levels in MPS VII mice were not significantly 
different from those of normal. (A) Circulating T3 level in normal and MPS VII mice at 
P14, 1 month, 2 months and 6 months of age (n≥9 replicates). (B) Circulating IHH level in 
normal and MPS VII mice at P14, 1 month and 2 months of age (n=replicates). Results are 
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5.2.4 Circulating IHH level was slightly decreased in MPS VII mice  
In normal mice, the circulating IHH level of mice was 54.0±16.5 ng/ml at 14 days of age 
and decreased with age (Figure 5.3B) such that at 6 months of age, the serum IHH level was 
no longer detectable. Circulating IHH level in MPS VII mice followed a similar pattern as 
that of normal mice and declined with age (Figure 5.3B). The circulating IHH level of MPS 
VII decreased to 37%, 57% and 67% of those of normal mice at P14, 1 month and 2 months 
of age, respectively, but did not reach statistical significance. At 6 months of age, serum 
IHH level of MPS VII mice was also not detectable.  
5.3 Liver derived IGF1 production 
5.3.1 GH-induced secretion of IGF1 was limited in MPS VII hepatocytes 
To further investigate the mechanism behind reduced level of circulating IGF1 in MPS VII 
mice, the effect of GH on IGF1 secretion by both normal and MPS VII hepatocytes was 
assessed in vitro. Normal hepatocytes produced IGF1 in response to GH stimulation in a 
dose dependent manner (Figure 5.4A). IGF1 level secreted by normal hepatocytes was 0.4 
± 0.22 pg/µg when cultured in the absence of GH, and it increased gradually with increasing 
concentrations of GH, and reached the peak (1.51 ± 0.09 pg/ µg) when cultured with 500 
ng/mL GH. In contrast, MPS VII hepatocytes produced significantly less IGF1 and did not 
display a dose-dependent increase. IGF1 levels secreted by MPS VII hepatocytes were 0.16 
± 0.05 pg/µg and 0.21 ± 0.06 pg/µg when cultured without GH and with 500 ng/mL GH, 
respectively. 
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Figure 5.4 GH-induced IGF1 production was limited in MPS VII hepatocytes but was 
rescued by β-glucuronidase (GUS). IGF1 secretion by (A) normal and MPS VII 
hepatocytes after 24hr of GH stimulation; and (B) normal and untreated MPS VII 
hepatocytes and β-glucuronidase rescued MPS VII hepatocytes after 24hr of GH stimulation 
(500ng/ml). Results are presented as mean ± S.E.M. 
* denotes significant difference of IGF1 secretion between normal and MPS VII 
hepatocytes. 
† denotes significant difference of IGF1 secretion by normal hepatocytes between GH doses 
and 0 ng/ml. 
# denotes significant difference of IGF1 secretion by normal hepatocytes between 
stimulation of 10ng/ml GH and 500ng/ml GH. 
§ denotes significant difference of IGF1 secretion by normal hepatocytes or GUS rescued 
MPS VII hepatocytes to untreated (uTx) MPS VII hepatocytes. 
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5.3.2 IGF1 secretion in MPS VII hepatocytes was rescued by β-glucuronidase (GUS) 
MPS VII hepatocytes were cultured in medium supplemented with β-glucuronidase 
(Chapter 2.7.3) to investigate whether IGF1 secretion by MPS VII hepatocytes is rescued 
by β-glucuronidase. Figure 5.4B shows that while untreated MPS VII hepatocytes failed to 
increase the IGF1 level (4.8±0.4% of normal) in response to GH stimulation, MPS VII 
hepatocytes supplied with β-glucuronidase produced an IGF1 level (120.5±3.1% of normal) 
that was equivalent to that of normal cells. 
5.3.3 Low IGF1 production in MPS VII liver was not due to deficiency of GHR but an 
impaired hepatic JAK2-STAT5 signalling  
In the liver, GH binds to GHR and subsequently activates phosphorylation of JAK2 and 
STAT5. The latter then forms a dimer structure and translocates into the nucleus, where it 
targets and induces transcription of Igf1. Hepatic GH signalling was therefore investigated 
in MPS VII liver using real-time PCR and immunohistochemistry analyses. 
Real-time PCR analyses revealed that the levels of expression of Ghr, Igf1, Igfbp3, Igfals, 
and Stat5a and Stat5b were not altered in the liver of MPS VII mice (Figure 5.5A) when 
compared to those of normal mice. However, a 5.6-fold higher level of Igfr1 expression was 
observed in the MPS VII liver when compared to normal liver (Figure 5.6A, p<0.05). 
Hepatocyte cytoplasm stained positive for GHR in both normal and MPS VII liver (Figure 
5.5B). Consistent with gene expression analyses, immunostaining of GHR within the MPS 
VII liver was at a similar level to that within the normal liver. Positive staining of Y-phos-
JAK2 was observed only in the nucleus of hepatocytes (Figure 5.5B) of both normal and 
MPS VII mice. More MPS VII liver cells were positive for Y-phos-JAK2 (145.5±12.3% of 
normal, p<0.05, Figure 5.5C).   
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Figure 5.5 MPS VII liver had elevated phosphorylated JAK2 in the nuclei. (A) Gene 
expression analysis of essential growth factors of GH/IGF1 axis in the liver. (B) IHC and 
quantification of hepatocytes positive for for GHR and Y-phos-JAK2. Scale bar=20μm. 
Results are presented as percentage of positive stained cells to total cells. Results were 
presented as the mean ± S.E.M. of n=5 replicates. 
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Y-phos-STAT5 was located within the cytoplasm of hepatocytes of both normal and MPS 
VII mice (Figure 5.6A). Fewer cells within the MPS VII liver (80.6±7.6% of normal, 
p<0.05, Figure 5.6B) stained positive for Y-phosp-STAT5 when compared to those within 
the normal liver. Immunostaining of Y-phos-STAT5A was not detected in neither normal 
nor MPS VII liver (data not shown). Immunostaining of S-phos-STAT5 was found in the 
nuclei of hepatocytes and was not significantly different between normal and MPS VII mice. 
 
Figure 5.6 Immunohistochemical staining of D14 mice liver for Y-phos-STAT5 and S-
phos-STAT5. IHC (A) and quantification (B) of hepatocytes positive for Y-phos-STAT5 
and S-phos-STAT5. Scale bar=20μm. Results are presented as percentage of positive 
stained cells to total cells, mean ± S.E.M of n=5 replicates.  
































98 | P a g e  
 
5.4 Discussion 
During childhood, bone growth is regulated by circulating GH, IGF1 (Baker et al. 1993; 
Liu, JP et al. 1993), thyroid hormones and glucocorticoids, whereas sex steroids contribute 
to this process later during puberty. MPS children have normal thyroid hormone levels but 
a high proportion of patients display GH insensitivity (Gardner et al. 2011; Toledo et al. 
1991). The overall endocrine status of MPS children is still uncertain. In this chapter, the 
status of GH, IGF1, IHH and T3 in normal and MPS VII mice at different ages was 
determined.  
GH does not affect postnatal growth in mice until after 14 days of age (Isaksson et al. 1987; 
Lupu et al. 2001; Zhou, Y et al. 1997). Therefore, GH secretion in normal and MPS VII 
mice was assessed from P14. Basal secretion of GH in the circulation of young MPS VII 
mice was not pronouncedly different to that of normal mice at P14 and 1 month of age. 
Acylated ghrelin injection greatly stimulated GH secretion, acting through the ghrelin 
receptor/GH secretagogue receptor (GHSR) (Kojima et al. 1999), in both normal and MPS 
VII mice at 1 and 4 months of age. A failure of GH secretion in MPS VII mice in response 
to ghrelin stimulation was observed at 2 months of age. However, it is still not understood 
what causes this age-specific failure of ghrelin-induced GH secretion in MPS VII mice. 
Young MPS VII mice had a markedly reduced circulating IGF1 level, which is likely to be 
the most direct cause of the observed bone shortening at the same ages. GH and IGF1 
mediate postnatal bone growth coordinately during pubertal and post-pubertal periods; 
however, early postnatal bone growth is mediated predominately by IGF1 and to a less 
extent by GH (Mohan, S. et al. 2003). Liver-derived IGF1 is the major source of circulating 
IGF1 and is predominately mediated by GH. GH-induced IGF1 production by MPS VII 
hepatocytes was markedly reduced in vitro, suggesting that decreased IGF1 level in MPS 
VII may be due to an impaired GH/IGF1 signalling pathway in the liver. The significantly 
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reduced circulating levels of IGFALS and IGFBP3, which are mainly synthesized by 
hepatocytes and Kupffer cells respectively, lead to increased stability of the ternary complex 
and thus resulted in less available IGF1 for bone growth. However, the reduction of 
bioactive IGF1 in MPS VII mice was not caused by deficiency of Igf1, Igfbp3 or Igfals in 
the liver at the transcription level.  
The initial steps of GH-induced IGF1 production in the liver includes autophosphorylation 
of GHR and cytoplasmic JAK2. In the liver of MPS VII mice, expression of GHR was not 
altered at either the transcription or protein level, suggesting the reduced IGF1 production 
was not caused by deficiency of GHR. Surprisingly, phosphorylation of JAK2 at tyrosine 
1007/tyrosine 1008 site, which is the initial step for activation of JAK2 (Feng et al. 1997), 
was absent from cytoplasm of the hepatocytes in both normal and MPS VII liver, but more 
Y-phos-JAK2 was observed in the nuclei of MPS VII hepatocytes. Nuclear JAK2 has been 
previously observed in rat liver but its function is not yet known (Lobie et al. 1996; Ram & 
Waxman 1997). A previous study found that accumulation of phosphorylated STAT5 in 
vitamin A-deficient liver was induced by decreased expression of SHP-1, which 
subsequently decreased expression of the nuclear JAK2 (Murray et al. 2005). The observed 
accumulation of nuclear Y-phos-JAK2 in MPS VII liver therefore may be associated with 
the reduction of Y-phos-STAT5. However, it is not clear whether elevated nuclear 
phosphorylation of JAK2 is involved in the decreased secretion of hepatic IGF1 in MPS VII 
mice or not. 
GH-induced IGF1 production also requires dimerization and nuclear translocation of 
STATs, mainly STAT5B in the liver (Hosui & Hennighausen 2008). Both tyrosine and 
serine phosphorylation of STAT5 (Gebert, Park & Waxman 1997) can be activated by GH. 
Cytoplasmic Y-phos-STAT5 was markedly decreased in MPS VII liver, while nuclear S-
phos-STAT5 was not significantly different to that of normal livers. Gene expression of 
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Stat5a and Stat5b was not altered in MPS VII liver, indicating that the reduced Y-phos-
STAT5 expression was not due to changes at transcription level. Tyrosine phosphorylation 
of STAT5B (Y-phos-STAT5B) was not examined in this chapter due to the absence of 
commercially available antibody against Y-phos-STAT5B. In both normal and MPS VII 
liver, Y-phos-STAT5A was not expressed (data not shown), supporting that STAT5A is less 
abundant and less necessary for tyrosine phosphorylation in the liver (Waxman et al. 1995). 
Gene expression of Igf1, Igfbp3 and Igfals in MPS VII liver was not significantly different 
from normal liver. Together, these findings suggest that nuclear translocation of STAT5 is 
not affected in MPS VII liver, and thus the transcription of its downstream targeting genes 
(Igf1, Igfbp3 and Igfals) is not altered. However, the decreased secretion of IGF1 by MPS 
VII liver is likely to be a result of the decreased cytoplasmic tyrosine phosphorylation of 
STAT5 through an unknown mechanism, which affects IGF1 secretion at the post-
transcriptional level (Figure 5.7).  
Healthy hepatocytes express low levels of IGFR1 and it is not directly involved in GH-
induced IGF1 production (Butler et al. 1994). However, MPS VII liver expressed an 
elevated level of Igfr1. Previous reports have observed overexpression of IGFR1 in 
hepatocytes of subjects with chronic hepatitis B, chronic hepatitis C and liver cirrhosis 
(Kim, Park & Lee 1996; Stefano et al. 2006; Tao et al. 2000). Thus, elevated expression of 
Igfr1 in MPS VII liver most likely indicates abnormal liver function rather than a role in 
IGF1 production.  
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Figure 5.7 GH-mediated IGF1 production is impaired in MPS VII liver. Binding of GH 
triggers dimerization of the cell surface GHR, which activates JAK2 through 
phosphorylation. Activated JAK2 lead to phosphorylation of the GHR and subsequently 
cytoplasmic transcription factors including STAT5A and STAT5B. In MPS VII liver, 
cytoplasmic phosphorylation of STAT5 is diminished. Phosphorylated STATs dimerize and 
translocate to the nucleus, where they bind onto the promoter of target genes (etc. Igf1, 
Igfbp3 and Igfals). Nuclear phosphorylation of STAT5 is at normal level in MPS VII liver. 
However, the levels of IGF1, IGFALS and IGFBP3 in the circulation of MPS VII mice are 
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Addition of β-glucuronidase to MPS VII hepatocytes rescued IGF1 production. It is likely 
that exogenous β-glucuronidase reversed the effects on poor IGF1 secretion by removing 
the GAG storage in MPS VII hepatocytes in vitro (Derrick-Roberts et al. 2014; Macsai et 
al. 2012). This indicates that disruption of lysosomal machinery is responsible for the 
reduced IGF1 production in MPS VII liver. Intravenous administration of exogenous 
enzymes produced by lentivirus mediated gene therapy to MPS animal models has been 
reported to efficiently reduce GAG storage in MPS liver (Cotugno et al. 2010; Derrick-
Roberts et al. 2014). Thus, in vivo correction of the reduced IGF1 production is achievable 
in MPS since current therapies such as ERT and GT deliver most GAG degradation enzymes 
to the liver efficiently.  
Circulating T3 level was not pronouncedly different in MPS VII mice at different ages. T3 
has been reported to promote bone growth, especially during the pre-pubertal period (Xing 
et al. 2012), and is likely to act through IGF1 signalling (O'Shea et al. 2005; Wang, L, Shao 
& Ballock 2010) and the IHH/PTHrP loop (Stevens et al. 2000). While hypothyroidism has 
been reported in a case of MPS I patient with short stature (Mohanalakshmi, V. & S. 2014), 
another study reported normal circulating level of thyroid stimulating hormone and 
thyroxine in MPS VI patients (Decker et al. 2010). However, findings in this chapter 
suggested that bone shortening in MPS VII mice was not caused by a deficiency of T3. 
Circulating IHH level was decreased in P14 MPS VII mice, but the reduction did not reach 
statistical significance. A direct function of circulating IHH on linear bone growth have not 
been previously reported; however, some studies suggest that the Hedgehog signaling 
pathway has positive effects on hepatic IGF1 production (Matz-Soja et al. 2014; Vokes et 
al. 2008). It is possible that circulating IHH contributes partially to bone shortening in MPS 
VII mice through modulating hepatic IGF1 production. In addition, serum IHH levels 
decreased with age in both normal and MPS VII mice. If circulating IHH indeed can 
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promote bone growth through regulating hepatic IGF1, its activity is age-dependent, which 
is highly expressed during early postnatal period; or even prenatal period as IHH is an 
essential morphogen for embryonic development (Ingham & McMahon 2001). 
This is the first study to investigate the level of endocrine factors in a MPS animal model at 
different ages. The results showed that while the circulating GH level was similar in young 
normal and MPS VII mice, ghrelin-induced GH secretion was greatly reduced in MPS VII 
mice at 2 months of age. MPS VII mice had greatly reduced IGF1, IGFBP3 and IGFALS 
levels in the circulation and an altered IGF1: IGFBP3: IGFALS ratio which resulted in less 
bioavailable IGF1. The reduced IGF1 level was caused by impaired GH-induced IGF1 
secretion in the liver. Although the detailed mechanism underlying failure of IGF1 
production is still not clear, diminished tyrosine-phosphorylated STAT5 expression in MPS 
VII liver may be involved. Local effects of GH on postnatal longitudinal bone growth have 
also been proposed, which either acts directly on growth plate chondrocytes (Gevers et al. 
2009) or indirectly stimulates local secretion of IGF1 (Mohan, S. et al. 2003; Wang, J et al. 
2004). This chapter revealed an alteration in the GH/IGF1 axis in MPS VII mice during 
longitudinal bone development; and the next chapter will examine the effects of 
paracrine/autocrine factors on chondrocyte proliferation and differentiation in MPS VII 
growth plate.  
  








6 The proliferative capacity of growth plate 
chondrocytes in response to endocrine and 
paracrine/autocrine factors 
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6.1 Introduction 
Chondrocyte activity in the growth plate is tightly regulated by the coordinated activity of 
multiple proteins. These proteins include but are not limited to systemic factors GH/IGF1 
and T3, autocrine/paracrine factors IGF1 and IHH secreted by growth plate chondrocytes, 
their cartilage-specific receptors and downstream transcription factors (Mackie et al. 2008).  
GH acts on resting, proliferative and pre-hypertrophic chondrocytes through locally 
expressed GHR (Gevers et al. 2009; Isaksson, Jansson & Gause 1982) and also stimulates 
the production of IGF1 by resting and proliferative chondrocytes through JAK2/STAT5 
signaling (Gevers et al. 2009) and together they play major role in controlling proliferation 
(Mohan, Subburaman et al. 2003; Wang, J et al. 2004). GHR null mice exhibit retarded 
growth (Zhou, Y et al. 1997), shortened long bones, narrowed growth plate, reduced PZ and 
HZ height, and decreased proliferation rate (Lupu et al. 2001). Bone length of GHR null 
mice (Sims et al. 2000) and growth of GHR deficient patients (Backeljauw & Underwood 
2001) were only partially restored by IGF1 treatment, supporting that GH has both direct 
and IGF1-dependent action on promoting linear bone growth. Cartilage-specific IGF1 
(Wang, Y et al. 2006) and IGFR1 (Wang, Y et al. 2011) null mice exhibit reduced 
proliferation and increased apoptosis of chondrocytes in the growth plate. The former mice 
had reduced long bone growth, and the latter mice showed disorganized columnar structure 
of the growth plate and apparent growth retardation. These studies demonstrate the essential 
roles of GH, IGF1 and their receptors in controlling chondrocyte proliferation in the growth 
plate.  
Under normal condition, T3 acts primarily on RZ and PZ chondrocytes through TR-α 
(Ballock et al. 1999; Robson et al. 2000). T3 promotes chondrocyte hypertrophy and inhibits 
chondrocyte proliferation (Robson et al. 2000; Stevens et al. 2000). The effect of T3 on 
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growth plate chondrocytes is indirectly mediated via GHR, IGFR1 (O'Shea et al. 2005), 
PTHrP and PTHrPR (Stevens et al. 2000).  
IHH is produced by prehypertrophic chondrocytes and its action is mediated through its 
receptors PTC and SMO in the growth plate (St-Jacques, Hammerschmidt & McMahon 
1999; Zhang, XM, Ramalho-Santos & McMahon 2001). IHH induces chondrocyte 
proliferation through transcription factors of the GLI family, and inhibits transition of 
chondrocytes to terminal differentiation via the IHH/PTHrP feedback loop (Hilton et al. 
2005; Vortkamp et al. 1996). Deficiency of Ihh in mice leads to reduced chondrocyte 
proliferation and an expanded HZ in the growth plate (St-Jacques, Hammerschmidt & 
McMahon 1999), whereas overexpression of Ihh in mice lead to upregulated PTHrP 
expression and a delayed transition of chondrocytes from proliferative to hypertrophic 
phenotypes (Minina et al. 2001). Although its effect on chondrocyte proliferation is parallel 
to IGF1(Long, Zhang, et al. 2001), IGF1 can stimulate secretion of IHH by chondrocytes 
(Wang, Y et al. 2006; Yang, ZQ et al. 2017). MPS VII mice have a reduced gene expression 
level of Ihh in the growth plate (Metcalf et al. 2009), however; it is not clear whether the 
expression pattern of the morphogen IHH is affected in these mice.  
The effects of GH, IGF1 and T3 on chondrocyte proliferation have not been reported in 
MPS cartilage. this chapter aimed to investigate the relationship between local signalling 
pathways and growth plate dysfunctions in MPS VII mice. As a decreased Ihh expression 
has been reported, this chapter therefore hypotheses that the altered IHH signalling pathway 
limits proliferative capacity of growth plate chondrocytes in MPS VII mice. The ability of 
MPS VII chondrocytes to proliferate in response to exogenous GH, T3, IGF1 and IHH was 
assessed in vitro. In addition, the expression pattern of IHH and gene expression levels of 
components of the IHH/PTHrP feedback loop were examined in the growth plate. 
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6.2 Cell proliferation was reduced in MPS VII chondrocytes in response to GH 
stimulation 
GH rapidly stimulated cell proliferation in cultured normal growth plate chondrocytes at a 
concentration of 250 ng/mL, reaching 187.0±7.6% of untreated chondrocytes after 6 days 
of culture (Figure 6.1A). In contrast, a decrease of cell proliferation was observed in MPS 
VII chondrocytes on day 2 of culture. Cell proliferation of MPS VII chondrocytes was then 
slowly stimulated by exogenous GH, reaching 142.0±4.6% of untreated chondrocytes on 
day 6 of culture. The level of cell proliferation in GH-treated MPS VII chondrocytes was 
significantly lower than in normal chondrocytes on day 2, 4 and 6 of culture (p<0.05), 
suggesting that MPS VII chondrocytes were less capable of responding to GH stimulation.  
To further investigate the cause(s) of the poor response of MPS VII chondrocytes to GH 
stimulation, transcription levels of genes involved in GH signalling pathway were examined 
using RNA isolated from the whole growth plate (Chapter 2.7). Expression levels of Ghr, 
Stat5a and Stat5b in MPS VII growth plate were not significantly different to those of 
normal growth plate (Figure 6.1B), suggesting that the delayed stimulatory effects of GH 
on MPS VII chondrocytes were not due to changes in GHR or STAT5s at the transcription 
level. However, IHC analysis (Figure 6.1C) showed an altered GHR expression pattern in 
MPS VII growth plate at protein level. While GHR was predominately expressed in the RZ 
and PZ of normal growth plate, the number of cells stained positive for GHR was reduced 
to 26.4% and 25.2% of normal in the RZ and PZ of MPS VII growth plate, respectively.  
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Figure 6.1 GH-induced cell proliferation was limited in MPS VII chondrocytes due to 
GHR deficiency. Cell proliferation of growth plate chondrocytes in response to GH 
treatment, results were represented as % of untreated chondrocytes, mean ± S.E.M. of n=3 
replicates (A). Expression of genes involved in the GH signaling in the growth plate (B), 
mean ± S.E.M. of n=5 replicates. Immunohistochemical staining for GHR on P14 normal 
and MPS VII growth plate (C). Scale bar=50μm. IHC results were presented as percentage 
of positive stained cells to total cells in each zone, the mean ± S.E.M. of n=3 replicates.  
* denotes significant difference between normal and MPS VII chondrocytes. 
# denotes significant difference between GH treated and untreated control chondrocytes 
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6.3 Exogenous IGF1 did not stimulate on cell proliferation of chondrocytes in vitro 
IGF1 failed to stimulate cell proliferation by either normal or MPS VII chondrocytes (Figure 
6.2A). Gene expression levels of Igfr1, Igfbp2 and Igfbp3 were not significantly different to 
normal in MPS VII growth plate (Figure 6.2B), suggesting that activation of IGF1 signalling 
in the MPS VII growth plate was not affected at the transcription level.  
The expression pattern of IGF1 protein was then assessed in the growth plate using IHC 
(Figure 6.2C). IGF1 was predominately expressed in the RZ, early PZ and pre-HZ, and was 
absent from most HZ chondrocytes in the normal growth plate. The staining pattern of IGF1 
in the MPS VII growth plate was not obviously different to normal growth plate in the RZ 
and PZ. In contrast, the number of HZ cells stained positive for IGF1 increased to 2.2-fold 
of normal chondrocytes.  
6.4 T3 exhibited a rapid stimulatory effect on proliferation of MPS VII chondrocytes 
in vitro 
T3 significantly decreased cell proliferation at concentration of 10ng/ml in cultured normal 
chondrocytes on day 6 of culture (Figure 6.3A). In contrast, T3 rapidly increased cell 
proliferation in MPS VII chondrocytes to 126.6±4.6% of untreated control chondrocytes in 
the first 2 days of culture, which was significantly higher than time-matched normal 
chondrocytes. Cell proliferation of MPS VII chondrocytes was significantly decreased on 
day 4 and day 6 of culture as compared to day 2 of culture, reaching 105.2±1.1% and 
101.4±6.8% of untreated chondrocytes, respectively, which suggested that the stimulatory 
effect of T3 on MPS VII chondrocytes was diminished on day 4 and 6 of culture. Gene 
expression levels of Trα and Trβ in the MPS VII growth plate were not significantly 
different to normal growth plate (Figure 6.3B). 
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Figure 6.2 Cell proliferation of both normal and MPS VII chondrocytes was not 
respond to IGF1 treatment. Cell proliferation of normal and MPS VII in response to IGF1 
treatment (A). Results were presented as percentage of untreated chondrocytes, mean ± 
S.E.M. of 3 replicates. Expression of genes involved in the activation of IGF1 signaling in 
the growth plate (B), mean ± S.E.M. of 5 replicates Immunohistochemical staining for IGF1 
on P14 normal and MPS VII growth plate (C). Scale bar=50μm. IHC results were presented 
as percentage of positive stained cells to total cells in each zone, mean ± S.E.M. of 3 
replicates.  
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Figure 6.3 Cell proliferation of MPS VII chondrocytes was increased in response to T3 
treatment. Cell proliferation of chondrocytes in response to T3 (A). Results were presented 
as the mean ± S.E.M. of 3 replicates. (B) Gene expression of receptors for T3 in the growth 
plate. Results were presented as the mean ± S.E.M. of 5 replicates.  
* denotes significant difference between normal and MPS VII chondrocytes. 
# denotes significant difference between T3 treated and untreated control chondrocytes. 
## denotes significant difference between T3 treated on day 2 and other days of culture 
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6.5 IHH signalling pathway was dysregulated in MPS VII chondrocytes  
Cell proliferation of normal chondrocytes exhibited minimal response to exogenous IHH in 
vitro (Figure 6.4A). However, IHH significantly increased cell proliferation in cultured 
MPS VII chondrocytes on day 2 and 4 of culture.   
Expression of essential components of IHH signalling pathway was examined by real-time 
PCR analysis. As Ihh is expressed by pre-hypertrophic and hypertrophic chondrocytes and 
Pthrp is expressed by resting chondrocytes and early proliferating chondrocytes (St-Jacques, 
Hammerschmidt & McMahon 1999; Vortkamp et al. 1996), RNA isolated from whole 
growth plate was used to examine the expression of these genes. Micro-dissection of PZ of 
the growth plate (Chapter 2.9) enriched the genes expressed predominately by the 
proliferative chondrocytes, including Smo, Ptch1, Gli3, Pthrpr and Sox9.  
Real-time-PCR analysis (Figure 6.4B) showed that the gene expression of Ihh significantly 
decreased to 0.46±0.1 fold of normal in the MPS VII growth plate. In the PZ (Figure 6.4C), 
Smo expression was not obviously changed as compared to normal; however, Ptch1 
expression was significantly elevated at 2-fold of normal (p<0.05). IHH downstream 
repressor Gli3 expression significantly increased at 4.4±0.9 fold of normal (p<0.05).  
The expression of PTHrP was not significantly different to normal in the MPS VII growth 
plate (Figure 6.4B). In the MPS VII PZ, while expression of Runx2 was at a normal level, 
expression levels of Pthrpr and Sox9 were significantly increased to 4.4±0.7 and 3.1±0.6 
fold of normal, respectively (p<0.05, Figure 6.4C).  
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Figure 6.4 Exogenous IHH stimulated cell proliferation of MPS VII chondrocytes. Cell 
proliferation in response to IHH stimulation (A). Results were presented as the mean ± 
S.E.M. of 3 replicates. Gene expression of genes involved in IHH/PTHrP loop in the whole 
growth plate (B), and PZ of the growth plate (C). Results were presented as mean ± S.E.M. 
of 5 replicates. 
* denotes to significant difference of cell proliferation between IHH-treated normal and 
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To study the expression pattern of IHH in MPS VII growth plate, immunohistochemistry 
(Chapter 2.10) was used on the tibial growth plates of normal and MPS VII mice at P14, 1 
and 2 months of ages. Immunostaining of IHH was observed in P14 normal and MPS VII 
growth plate (Figure 6.5A) but was absent from the growth plate of both normal and MPS 
VII mice at 1 and 2 months of ages, suggesting that production of IHH in the growth plate 
decreases with age in both normal and MPS VII mice. At P14, immunostaining of IHH was 
predominately observed in the PZ and HZ of normal growth plate (Figure 6.5A). In contrast, 
the number of chondrocytes positive for IHH staining was significantly decreased to 25% 
of normal in the PZ of MPS VII growth plate p<0.05, Figure 6.5B).  
An increase in IHH secretion by normal chondrocytes was observed over the first 2 days of 
culture (Figure 6.5C). However, IHH secretion by MPS VII chondrocytes was significantly 
decreased, indicating an impaired secretion of IHH by cultured MPS VII chondrocytes.  
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Figure 6.5 IHH production was greatly reduced in MPS VII growth plate. 
Immunohistochemical staining for IHH on normal and MPS VII mice at P14, 1 month and 
2 months of age (A). Quantification results for P14 mice was represented were presented as 
percentage of positive stained cells to total cells in each zone (B). Level of IHH produced 
by normal and MPS VII chondrocyte in culture (C). Results were presented as the mean ± 
S.E.M. of 3 replicates. Scale bar=20μm. 
*denotes to significant differences between normal and MPS VII mice (p<0.05, Student’s 
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6.6 Discussion 
Proliferation and hypertrophic differentiation of chondrocytes in the growth plate 
contributes to the elongation of long bones. Proliferation is known to be regulated through 
multiple signally pathways including GH/IGF1 axis and the IHH/PTHrP loop. Hypertrophic 
differentiation is regulated by thyroid hormone and also the IHH/PTHrP loop (Mackie et al. 
2008). However, the effects of GH, IGF1, T3 and IHH signalling pathways on MPS VII 
chondrocytes remained unknown. This chapter therefore aimed to investigate the 
responsiveness of chondrocytes to exogenous GH, T3, IGF1 and IHH and the regulation of 
their corresponding signaling pathways in MPS VII growth plate.  
Exogenous GH stimulated cell proliferation in both normal and MPS VII chondrocytes, but 
proliferation was greatly reduced in MPS VII. The observed proliferative response to GH 
stimulation was consistent with previous studies on rabbit and rat (Madsen et al. 1983; 
Ohlsson, Nilsson, Isaksson & Lindahl 1992) growth plate chondrocytes. GH appears to act 
on PZ chondrocytes with resting and hypertrophic chondrocytes unresponsive to GH 
stimulation (Oberbauer & Peng 1995). MPS VII growth plates have a lower proportion of 
PZ chondrocytes than normal growth plate (Figure 3.8B). Pooled chondrocytes isolated 
from MPS VII growth plate therefore contained less PZ chondrocytes than normal growth 
plate. Since GH preferentially acts on proliferative chondrocytes (Oberbauer & Peng 1995), 
the reduced number of PZ chondrocytes in MPS VII growth plate may explain the reduced 
proliferative capacity of MPS VII cells. In addition, MPS VII RZ and PZ chondrocytes 
expressed less GHR than normal chondrocytes. As expression of GHR determines 
responsiveness to GH (Isaksson et al. 1990), less GHR would also contribute to reduced 
proliferation of MPS VII chondrocytes.  
Exogenous IGF1 failed to promote cell proliferation in both normal and MPS VII 
chondrocytes. This conflicts with the previous reported ability of IGF1 to stimulate 
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chondrocyte proliferation (Oberbauer & Peng 1995; Trippel et al. 1989). Differences in the 
species used (mouse versus cow, rabbit and rat), and anatomical site from which 
chondrocytes were isolated (proximal tibia growth plate versus distal radius growth plate 
and costochondral growth plate) may have contributed to the observed differences. The dose 
of IGF1 used for chondrocyte culture in this chapter was at a relatively high concentration 
compared to the literature; however, dose response assessment of IGF1 suggested lower 
concentrations of IGF1 (25ng/ml-250ng/ml) also did not stimulate chondrocyte 
proliferation (Figure 2.2). 
T3 had an inhibitory effect on cell proliferation of normal chondrocytes, but stimulated cell 
proliferation of MPS VII chondrocytes on day 2 of culture. T3, which acts through TRs 
expressed by the resting and proliferative chondrocytes, triggers initiation of proliferation, 
but subsequently inhibits further proliferation and promotes terminal differentiation 
(Robson et al. 2000; Williams 2013). Altered ratio of RZ to PZ cells found in MPS VII 
growth plate (Figure 3.8A and B) may contribute to the greater response to T3 in MPS VII 
chondrocyte culture. 
While IHH had no effects on normal chondrocyte proliferation, it significantly stimulated 
proliferation of MPS VII chondrocytes. IHH has been shown to promote cell proliferation 
of PZ chondrocytes isolated from the chick embryo sterna, but not RZ or HZ chondrocytes 
(Shimo, Tsuyoshi et al. 2008). Sonic hedgehog (SHH) protein, a variant of IHH, stimulated 
proliferation of chondrocytes isolated from 3 days old murine growth plate, but did not 
affect the proliferation of chondrocytes from 3 week old mice (Iwasaki, M, Jikko & Le 
1999). This study suggested that the function of SHH on proliferation is age dependent and 
is more effective on young chondrocytes. In the present chapter, normal and MPS VII 
chondrocytes were isolated from the growth plates of P14 mice, which falls between the 
above two ages. The unresponsiveness of normal chondrocytes to IHH in culture may 
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therefore be attributed to the age of the chondrocytes. Chondrocytes from P14 were older 
and less effective than chondrocytes from 3 days old mice to respond to IHH. In contrast, 
although MPS VII chondrocytes were obtained from age-matched animals, they expressed 
an elevated level of Ptch1 in the PZ, the receptor of IHH. Thus, exogenous IHH stimulated 
cell proliferation in MPS VII chondrocytes culture.  
A reduction of IHH expression was noticed in the whole MPS VII growth plate at the 
transcription level, which was consistent with a previous finding (Metcalf et al. 2009). The 
level of IHH protein secreted by MPS VII chondrocytes was also greatly decreased in both 
the PZ of MPS VII growth plate and in culture. As a result, proliferation of chondrocytes, 
which is partially regulated by IHH (Long, Zhang, et al. 2001; Razzaque et al. 2005), was 
reduced (Figure 3.8B). This hypothesis can be supported by the observation of elevated Gli3 
expression in the PZ of MPS VII growth plate (Figure 6.6). Less IHH is available to bind to 
PTC for downstream activation of SMO, increasing the expression of Gli3.  Transcription 
of IHH target genes is therefore repressed and chondrocyte proliferation in MPS VII growth 
plate is limited. However, in this chapter expression of Smo in the MPS VII PZ was not 
apparently different to that of normal PZ at the transcription level. Further investigations 
are required to assess if the protein level of SMO or activation of SMO is affected in MPS 
VII growth plate.  
While this chapter focused on the proliferative response of chondrocytes, the results 
suggested that transition to the hypertrophic phenotype was also altered. In addition to 
promoting proliferation, IGF1 promotes linear bone growth by controlling the expansion of 
hypertrophic chondrocytes (Wang, J, Zhou & Bondy 1999). As shown in Figure 6.2C, IGF1 
is expressed in the pre-HZ of normal growth plate and is subsequently reduced in the HZ as 
chondrocytes mature. In contrast, a higher proportion of MPS VII chondrocytes continued 
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to express IGF1 in the HZ, indicating that transition of MPS VII chondrocytes from 
proliferation to hypertrophic differentiation is delayed.  
The levels of SOX9, PTHrP and its receptor need to be downregulated to allow hypertrophic 
differentiation of chondrocytes (Huang, W et al. 2001; Kronenberg 2003; Weir et al. 1996). 
However, elevated gene expression levels of Pthrpr and its downstream target Sox9 were 
observed in the PZ of MPS VII growth plate. PTHrP is synthesized by RZ chondrocytes, 
diffusing to the PZ and pre-HZ chondrocytes where it bound by PTHrPR during postnatal 
growth (Chau et al. 2011; Lee, K et al. 1996; Schipani et al. 1997). Alteration of gene 
expression level of PTHrP in MPS VII growth plate would be masked by the whole growth 
plate. Therefore, in this chapter, examination of PTHrP level was assessed indirectly by the 
expression of Pthrpr that is expressed by the PZ chondrocytes. Persistent SOX9 protein was 
observed in canine vertebral chondrocytes during proliferative to hypertrophic maturation 
(Peck et al. 2015). Thus, it is likely that persistent levels of Pthrpr and Sox9 in the PZ result 
in delayed transition of MPS VII chondrocytes from proliferation to hypertrophic phenotype 
(Figure 6.6). In addition, as IHH and PTHrP form a negative feedback loop (Minina et al. 
2002; Vortkamp et al. 1996) in the growth plate, an increase of PTHrP would limit IHH 
secretion by pre-hypertrophic chondrocytes, which could explain the reduced IHH level 
observed both in vitro and in vivo in MPS VII chondrocytes.  
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Figure 6.6 Altered IHH/PTHrP signalling in MPS VII growth plate. Chondrocyte 
proliferation in MPS VII growth plate is inhibited by decreased IHH expression and elevated 
Ptch1 and Gli3. Transition of MPS VII chondrocytes to hypertrophy is also inhibited by 
persistent expression of Pthrpr and Sox9. Arrows indicate stimulatory pathways, while 
crossed lines indicate inhibitory pathways. Red arrows indicate upregulated genes and green 
arrows indicate downregulated proteins.  
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In summary, the regulation of proliferation in MPS VII chondrocytes as well as their 
transition to hypertrophic differentiation was affected due to dysfunctions of GH, IGF1 and 
IHH signalling pathways. MPS VII chondrocytes had less capacity to proliferate in response 
to GH stimulation, due to reduced expression of GHR in the RZ and PZ. Proliferation of 
chondrocytes may also be limited by the reduction of IHH in MPS VII growth plate. 
However, exogenous IGF1 does not play a role on chondrocyte proliferation in culture. In 
addition, this chapter found that more MPS VII HZ chondrocytes continued to express IGF1, 
indicating a phenotype more characteristic of proliferative chondrocytes. The persistent 
expression of Pthrpr and Sox9 by PZ chondrocytes also suggested that proliferative 
phenotype were maintained in MPS VII growth plate instead of transiting to hypertrophic 
differentiation. 
  









7 General Discussion 
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The majority of bones in the human skeleton are formed through the process of 
endochondral ossification that originate from a cartilage template (Abad et al. 2002; Long 
& Ornitz 2013; Mackie, Tatarczuch & Mirams 2011). This process is controlled by a 
complex network of endocrine factors, paracrine/autocrine factors, transcription factors as 
well as cell cycle regulators, which are well characterized under the normal condition. 
However, limited attention has been given to bone development in MPS patients and animal 
models. Pathogenesis of reduced bone length in MPS is still not understood. This thesis 
firstly sought to address the progression of bone growth defects in different MPS mouse 
models. Second to this, potential signalling pathways that are affected in MPS VII during 
endochondral bone development were determined.  
7.1 Shortened long bone growth in MPS VII mice is a result of dysfunction of the 
EO from early ages 
Initial evaluation of long bone and vertebral lengths at maturity revealed that the reduction 
in bone lengths at maturity was greatest in the severe MPS VII (Gusmps/mps strain) murine 
model (Figure 3.1), and were consistent with human (Montano et al. 2016; Sly et al. 1973), 
canine (Herati et al. 2008; Smith, LJ et al. 2012) and feline MPS VII (Fyfe et al. 1999; 
Wang, P et al. 2015). Femur and tibia lengths were significantly shorter than normal from 
P14 of age onwards and growth rate worsened with age (Figure 3.2), which are consistent 
with MPS patients whose bone growth velocities decline significantly after one year of age 
(Kubaski et al. 2016; Montano et al. 2016; Montaño et al. 2008; Patel, Suzuki, Maeda, et al. 
2014; Quartel et al. 2015; Rozdzynska-Swiatkowska et al. 2015).  
7.1.1 MPS VII mice have delayed formation of ossification centres from early ages 
Development of the POC and SOC in MPS VII tibia followed the same pattern as in normal 
mice; however, the process of EO was delayed in utero (development of the POC) and 
124 | P a g e  
 
worsened during postnatal long bone growth (development of the SOC and growth plate) 
(Figure 3.3-3.5). Chondrocytes started to differnetiate to hypertrophic chondrocytes from 
the middle of the diaphysis in both normal and MPS VII mice at ~E14.5. Formation of the 
POC that is characterized by blood vessel invasion and bone deposition initiated at ~E15.5 
in normal mice, whereas it was approximately one day delayed in MPS VII mice (Figure 
3.3A). This delay in development coincides with the first appearance of storage material in 
chondrocytes of MPS VII mice (Vogler et al. 2005), suggesting a relationship between 
cellular storage and the abnormal formation of the POC. Early storage has also been 
observed in placenta tissue of MPS II and VI patients (Baldo et al. 2011); however, it is still 
not known whether chondrocytes from MPS human foetus have storage or not. While 
hypertrophic chondrocytes were first observed at P7 in the middle of epiphysis of both 
normal and MPS VII mice, initiation of the SOC in most MPS VII mice was observed at 
P12, which is approximately two days later than that of normal (Figure 3.4A). A similar 
delay in the deposition of bone in the SOC was observed in MPS VII dog vertebrae, femur 
and tibia (Peck et al. 2015). Findings from this theise suggested that bone deposition was 
delayed in MPS VII mice, which was more pronounced in the SOC after birth than the POC 
in utero, coinciding with a greater degree of GAG storage in older chondrocytes. 
Both normal and MPS VII chondrocytes underwent hypertrophic expansion at the same 
time in the POC and SOC. However, in this study hypertrophic expansion was defined by 
an increase in cell volume (Cooper et al. 2013; Farnum et al. 2002). Their ability and the 
ability of bone, endothelial and perichondrial cells to support angiogenesis and osteogenesis 
was not examined. Previous studies have observed decreased expression of MMP13 in 3 
weeks old MPS VII tibia (Metcalf et al. 2009) and reduced collagen II degradation, which 
is mediated by cathepsin K, in MPS I osteoclasts (Wilson, S et al. 2009). These suggested 
that MPS VII hypertrophic chondrocytes may not express one or more of the enzymes for 
matrix remodelling (such as MMPs) and growth factors (such as VEGFs) for invasion of 
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blood vessels to the same extent as normal, leading to the subsequent delay in bone 
deposition in MPS VII tibia.  
These enzymes and growth factors are regulated by paracrine/autocrine factors during bone 
development. MMP2, MMP3, MMP9 and MMP13 can be induced by PTH/PTHrP 
(Chiusaroli et al. 2003; Kawashima-Ohya et al. 1998; Selvamurugan et al. 2000). MMP13 
expression can also be promoted by IHH in osteoarthritis cartilage (Wei et al. 2012). 
Vascularization can be regulated by IGF1 through hypoxia, which upregulates VEGF 
expression (Piecewicz et al. 2012). Indeed, altered Ihh and Pthrpr expression in the growth 
plate (Figure 6.4) and reduced circulating IGF1 level (Figure 5.2) were observed in MPS 
VII mice. The former would delay chondrocyte hypertrophy (discussed in section 7.1.3), 
which disrupts the secretion of MMPs and the latter would contribute to poor vascularization 
and bone deposition (Akeno et al. 2002; Mochizuki et al. 1992), and thus these altered 
signalling pathways could lead to delayed formation of ossification centres in MPS VII 
mice. Further studies linking these altered signalling pathways to matrix degradation and 
vascularization are required to understand the mechanism behind the delayed formation of 
ossification centres in MPS VII mice. 
7.1.2 The number of MPS VII chondrocytes transit to proliferative status was reduced  
Histomorphometric analysis showed that the number of chondrocytes was significantly 
decreased in MPS VII PZ (Figure 3.8B). Chondrocytes proliferation is strictly controlled by 
synchonized cell cycle progression (Beier 2005; LuValle & Beier 2000). CyclinD1 and its 
downstream target E2F1 are highly expressed in the RZ and early PZ of the growth plate 
for G1-S phase transition (Figure 4.1 and 4.3). E2F1 induces transcription of genes involved 
in DNA replication, such as CyclinE, CyclinA, minichromosome maintenance proteins 
(MCMs) and DNA polymerases during late G1-S phase (Ohtani, DeGregori & Nevins 1995; 
Ren et al. 2002). Chondrocytes in the PZ then undergo rapid DNA replication and mitotic 
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division for several rounds and withdraw from the cell cycle for terminal differentiation to 
the hypertrophic phenotype.  
An increased number of chondrocytes stained postive for Ki67 and E2F1 was observed in 
MPS VII PZ (Figure 4.3). However, fewer MPS VII chondrocytes stained posititve for phos-
hisH3 a marker for mitosis (Figure 4.4). Although the number of chondrocytes in the S 
phase was not examined in this thesis, a previous study reported a reduced prolfieration rate 
in MPS VII PZ using BrdU staining, indicating a reduction in DNA replication (Metcalf et 
al. 2009). These results suggested that although more MPS VII chondrocytes were in the 
G1 phase and had committed to enter the S phase, progression to DNA replication and 
mitotic division was reduced through an as yet unknown mechanism.  
Upon entry to S phase, regulators of G1-S phase transition, such as Cyclin D1, Cyclin E and 
E2Fs are dispensable and therefore are degraded by proteasomes in an ubiquitination-
dependent manner (Alt et al. 2000; Clurman et al. 1996; Hateboer et al. 1996; Koepp et al. 
2001; Lin, DI et al. 2006; Marti et al. 1999). Although it has not been reported that 
ubiquitination of these proteins are regulated by lysosomal pathways, impairment of the 
ubiquitin-dependent protein degradation has been observed in MPS VI and other lysosomal 
storage disorders (Bifsha et al. 2007; Tessitore, Pirozzi & Auricchio 2009). Therefore, it is 
likely that ubiquitin-dependent degradation of Cyclin D1 and E2F1 would be inhibited by 
lysosomal storage in MPS VII chondrocytes, resulting in increased levels of these 
molecules.  
Chondrocyte proliferation is also promoted by signalling pathways including GH, IGF1 and 
IHH (Isaksson, Jansson & Gause 1982; Isgaard et al. 1988; Long, Zhang, et al. 2001). 
Although the circulating GH level was normal in MPS VII mice (Figure 5.1), fewer MPS 
VII chondrocytes expressed GHR in the RZ and PZ as compared to normal mice (Figure 
6.1). Cell proliferation of MPS VII chondrocytes in response to GH stimulation was greatly 
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reduced compared to normal chondrocytes (Figure 6.1). GH directly induces resting 
chondrocytes to proliferate through GHR signalling (Baker et al. 1993; Gevers et al. 2009; 
Hunziker, Wagner & Zapf 1994; Isaksson, Jansson & Gause 1982). It also promotes 
proliferation preferentially by the PZ chondrocytes (Oberbauer & Peng 1995). As MPS VII 
mice exhibited fewer number of chondrocytes in the PZ (Figure 3.7) and fewer of these cells 
expressed GHR, the proliferative capacity of MPS VII chondrocytes in response to GH was 
therefore reduced.  
MPS VII mice had reduced circulating IGF1 levels (Table 5.1 and Figure 5.2), which is 
consistent with several cases of MPS patients (Gardner et al. 2011; Toledo et al. 1991). 
Although GHR, the primary mediator of GH-induced IGF1 production, was deficient 
(Figure 6.1), local secretion of IGF1 was not affected in MPS VII PZ (Figure 6.2). The 
relative roles of endocrine (circulating) and autocrine/paracrine (local) IGF1 on skeletal 
growth are controversial in the last two decades. Liver-specific ablation of Igf1 gene at birth 
in mice showed a marked reduction (75% of normal) in the circulating IGF1 level, but 
normal bone growth at post-weaning ages (Yakar et al. 1999), suggesting that endocrine 
IGF1 is not necessary for longitudinal bone growth at later postnatal ages. Ablating the Igf1 
gene at 24-28 days after birth reduced circulating IGF1 to a similar level as above (Sjogren 
et al. 1999). It is likely that the low, but detectable serum IGF1 is sufficient to support 
normal postnatal bone growth. Decreased growth plate height, but not bone shortening of 
hepatic Igf1 and Igfals double knockout mice was restored by IGF1 treatment (Yakar et al. 
2002), suggesting that endocrine IGF1 promotes linear bone growth through the growth 
plate. Knockout of GHR in mice lead to reduced endocrine and autocrine/paracrine IGF1 
levels, resulting in significantly decreased femur length and bone mass (Wu, Y et al. 2013). 
However, normalization of endocrine IGF1 level was not sufficient to restore these skeletal 
phenotypes, indicating that autocrine/paracrine IGF1 is also essential to coordinate linear 
bone growth. It is likely that circulating IGF1 (75% of which is liver derived) mainly 
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promotes bone deposition during endochondral ossification, and is essential during 
embryonic and early postnatal bone growth (Baker et al. 1993; Wang, Y et al. 2006). 
Circulating IGF1 also promotes chondrocyte proliferation (Yakar et al. 2002). If circulating 
IGF1 is indeed important for promoting chondrocyte proliferation, the reduced number of 
PZ chondrocytes (Figure 3.7) would be attributed to the decreased bioactive IGF1 level in 
the circulation of MPS VII mice. 
Findings of deficient GHR in the growth plate and reduced IGF1 level in the circulation in 
MPS VII mice may explain the failure of GH therapy to improve bone growth in MPS 
patients (Gardner et al. 2011; Polgreen & Miller 2010; Polgreen et al. 2009; Polgreen et al. 
2014). It is possible that GH therapy alone or the dose of GH used in the above trails is not 
sufficient to benefit bone growth of MPS patients with short stature. Early treatments prior 
to the onset of bone shortening may have better effects since the function of endocrine IGF1 
on linear bone growth is essential for embryonic and early postnatal development (Baker et 
al. 1993; Wang, Y et al. 2006).  
Both gene expression of Ihh and the number of chondrocytes that stained positive for IHH 
were significantly decreased in the PZ of MPS VII growth plate (Figure 6.4 &6.5). These 
observations were accompanied by an elevated gene expression level of Gli3, suggesting a 
reduction in the IHH signalling pathway, which is associated with the reduced proliferation 
in the MPS VII growth plate (Long, Zhang, et al. 2001; Razzaque et al. 2005). Secretion of 
IHH by chondrocytes is stimulated by IGF1(Wang, Y et al. 2006; Yang, ZQ et al. 2017); 
thus, it is possible that the decreased IHH secretion in the PZ is caused by the reduction of 
circulating IGF1 in MPS VII mice (Table 5.1 and Figure 5.2). In addition, IHH has been 
shown to be inhibited by interleukin-1β (IL-1β), a pro-inflammatory cytokine (Thompson, 
CL et al. 2015). Inflammation occupies a critical role in lysosomal storage disorders 
(Calogera 2016) and MPS (Simonaro et al. 2005; Simonaro et al. 2010; Simonaro, Haskins 
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& Schuchman 2001). Although evidence indicating the relationship between inflammation 
and the altered IHH signalling pathway in MPS has not yet been reported, downregulation 
of inflammation either by knockout of toll-like receptor 4 or use of anti-inflammatory drugs 
has been shown to have normalized structure of the growth plate in MPS VII mice and small 
improvements on bone growth of MPS IV rats receiving ERT, respectively (Eliyahu et al. 
2011; Simonaro et al. 2010). Further studies are required to reveal the relationship between 
inflammation in MPS and the altered signalling pathways observed in this thesis.  
However, although GH, IGF1 and IHH are known to promote chondrocyte proliferation, 
and that CyclinD1 is a downstream target of both IGF1 and IHH (Mairet-Coello, Tury & 
DiCicco-Bloom 2009; Tian et al. 2014), a direct relationship between GH, IGF1 and IHH 
and cell cycle regulators has not been shown in this study.  
7.1.3 Transition of chondrocyte to hypertrophic differentiation was delay in MPS VII 
mice 
Histomorphometric analysis showed that the number of chondrocytes was lower than 
normal (Chapter 3.4, Figure 3.8C), suggesting that fewer proliferative chondrocytes 
differentiate to hypertrophic chondrocytes in MPS VII growth plate. Chondrocytes 
withdraw from the cell cycle to embark upon hypertrophic differentiation. The decision by 
chondrocytes to exit the cell cycle is made during G1 phase (Zetterberg & Larsson 1985). 
Normal chondrocytes in the pre-HZ and HZ express p57kip2 highly (Chapter 4.4, Figure 4.5), 
which downregulates CyclinD1/CDK activity. E2F4 proteins enter the nucleus of these 
chondrocytes and form complexes with pocket proteins (pRb, p130 and p107) to inhibit 
E2F1. Transition to S phase is therefore limited and chondrocytes exit the cell cycle for 
hypertrophic differentiation.  
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Significantly fewer MPS VII HZ chondrocytes expressed p57kip2 (Figure 4.5); instead these 
cells continued to express CyclinD1 and higher levels of phos-pRb and E2F1 (Figure 4.1, 
4.2A & 4.3A). These observations indicated that fewer MPS VII HZ chondrocytes withdrew 
from the cell cycle for hypertrophic differentiation. 
The transition of chondrocytes to the hypertrophic phenotype is also regulated by 
coordinated signalling pathways including IGF1 signalling pathway and IHH/PTHrP 
negative feedback loop. While local IGF1 was downregulated in normal HZ, a higher 
proportion of MPS VII chondrocytes continued to express IGF1 in the HZ (Figure 6.2). 
Although it has not been reported in cartilage cells, IGF1 downregulates p57kip2 and 
upregulates CylinD1 in cortical precursor cells in vitro, which is potentially mediated 
through the PI3K/AKT/GSK3β-dependent signalling pathway (Isgaard et al. 1988; Mairet-
Coello, Tury & DiCicco-Bloom 2009; Schlegel et al. 2010). Thus, the limited cell cycle 
withdrawal for hypertrophic differentiation may be partially due to the elevated 
autocrine/paracrine production of IGF1 in the HZ of MPS VII growth plate.  
Gene expression of Pthrpr and Sox9 was elevated in the PZ of MPS VII growth plate as 
compared to age-matched normal PZ (Figure 6.4). Consistent with this finding, persistence 
of SOX9 protein was observed in MPS VII dog vertebrae epiphyseal chondrocytes during 
proliferative-hypertrophic turnover (Peck et al. 2015). PTHrP maintains chondrocytes at 
proliferative stage by promoting SOX9; and delays chondrocyte hypertrophy by repressing 
RUNX2 and p57kip2 (Guo et al. 2006; MacLean et al. 2004). Altered PTHrP signalling in 
the PZ therefore would maintain the proliferative phenotype of MPS VII chondrocytes 
through increased expression of Pthrpr and Sox9 and delay their transition to hypertrophic 
differentiation by inhibiting p57kip2-dependent cell cycle withdrawal.  
131 | P a g e  
 
7.2 Summary 
While this thesis demonstrated that Gusmps/mps mice representing severe MPS VII displayed 
the greatest reduction in bone elongation, findings from this thesis also have direct relevance 
for other MPS types displayed bone growth defects. A detailed picture of long bone 
development during the latter part of pregnancy and the postnatal period in MPS VII mice 
has been drawn. In addition, a potential mechanism to explain growth plate dysfunction in 
MPS VII mice is presented (Figure 7.1). The main findings from this thesis are: 
1) Programmed formation of the POC and SOC is delayed in MPS VII mice. 
2) Chondrocyte proliferation is reduced in MPS VII growth plate, due to disrupted 
progression of chondrocytes to mitotic division, reduced circulating IGF1 levels, decreased 
capacity of MPS VII chondrocytes to respond to GH due to GHR deficiency and reduced 
secretion of IHH by MPS VII chondrocytes. 
3) Hypertrophic differentiation is also delayed as MPS VII HZ chondrocytes maintain 
proliferative phenotype and do not withdrawal from the cell cycle due to persistent local 
IGF1 and expression of Pthrpr and Sox9.  
Collectively, these findings suggested that reduced proliferation and hypertrophy in the 
growth plate are both implicated in bone shortening in MPS VII mice. However, there are 
some limitations in this thesis. Alteration of cell cycle regulators and local factors were 
characterized based on the observation of expression pattern in the growth plate using 
immunohistochemistry but was not quantitatively analysed. In addition, GH is secreted in a 
pulsatile manner, which would fluctuate widely in elder animals. Although GH level in elder 
mice was amplified by ghrelin injection, it would better to assess GH level using serum 
samples collected at short intervals (Huang, L et al. 2014). 
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To date, no published studies have investigated comprehensively the growth retardation in 
MPS by studying bone shortening, growth plate dysfunction and regulation of endochondral 
ossification using murine models. Our novel findings have provided a detailed picture of 
MPS VII bone phenotype and growth plate dysfunction, which will guide future directions 
of investigating the mechanism behind the growth failure in MPS. This thesis also has 
highlighted the fact that bone phenotypes of MPS are established before birth, which may 
explain the difficulty experienced by clinicians and researchers in improving bone growth 
by therapies initiated during childhood.  
 
 
Figure 7.1 Interaction of altered signalling pathways and cell cycle progression in MPS 
VII growth plate. Transition of chondrocytes to proliferation (DNA replication) is 
downregulated by GHR deficiency in the RZ and PZ. Later, mitotic division in the PZ 
chondrocytes is inhibited due to reduced bioactive IGF1 in the circulation and 
downregulated secretion of IHH by MPS VII chondrocytes. As a result, proliferation of 
MPS VII chondrocytes is limited. Fewer MPS VII HZ chondrocytes withdraw from the cell 
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CyclinD1 and E2F1 in the HZ, which could be attributed to persistence of local IGF1 and 
expression of Pthrpr and Sox9 in MPS VII growth plate.  
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Appendix A: Materials 
Agarose, DNA grade                                                Progen Biosciences, QLD, Australia 
 
Alician Blue 8GX                                             Sigma-Aldrich Pty. Ltd., NSW, Australia 
  
Alizarin Red S                                                        ProSciTech Pty. Ltd., QLD, Australia 
 
Bovine Serum Albumin (BSA)                         Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Bradford assay kit                                     Bio-Rad Laboratories Pty., Ltd., NSW, Australia 
 
Cell and Tissue Staining Kit(anti-rabbit and anti-goat)   R&D systems, Minneapolis, USA 
 
Chloroform                                                 Invitrogen Australia Pty. Ltd., VIC, Australia 
 
Citric acid                                                     Ajax Finechem Pty. Ltd., Seven Hills, NSW 
 
CyQUANT® Direct Cell Proliferation Assay Kit           Molecular Probes, Invitrogen 
Australia Pty. Ltd., VIC, Australia 
 
dNTPS                                                              Roche Diagnostics, Mannheim, Germany 
 
Diethylpyrocarbonate (DEPC)                         Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Dulbecco’s PBS                                              JRH Biosciences Pty. Ltd., VIC, Australia 
 
EDTA                                                     BDH (Merck) Pty. Ltd., Kilsyth, VIC, Australia 
 
Ethidium Bromide                                           Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Fast Green                                                             ProSciTech Pty. Ltd., QLD, Australia 
136 | P a g e  
 
 
Fetal calf serum                                             Life Technologies Pty. Ltd., VIC, Australia 
 
Fluorescein isothiocyanate (FITC) (#656111)                            ThermoFisher, Australia  
 
Geltrex LDEV-Free hESC-qualified reduced growth factor basement membrane matrix                     
Thermofisher, Australia 
 
Ghrelin (#AS-24159)                                                                    AnaSpec Inc, CA, USA 
 
Glycine                                        Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
 
H2O2                                                                    BDH (Merck) Pty. Ltd., VIC, Australia 
 
Hams F-12                                                        Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Horse serum (#16050130)                                                          ThermoFisher, Australia 
 
ImmunocalTm                                                                      Decal Corporation, NY, USA 
 
Isoflurane                                                                               Abbott Australasia Pty. Ltd. 
 
Isopropanol                                 Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
 
Leica CV Mounting Media                       Leica Microsystems Pty Ltd, NSW, Australia 
 
Lithium Chloride (LiCl)                                  Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Lithium  Carbonate (Li2CO3        Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
 
Magnesium Chloride (MgCl2)                                       Roche Diagnostics, Mannheim, Germany 
 
Mayer’s hematoxylin                                             ProSciTech Pty. Ltd., QLD, Australia 
 
Mouse GH ELISA kit (EZRMGH-45K)                                                             EMD Millipore, USA 
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Mouse/rat IGF1 Quantikine ELISA kit (MG100)                                          R&D systems, USA 
 
Mouse IGFALS ELISA kit (MBS912703)                      MyBioSourse Inc, San Diego, USA 
 
Mouse IGFBP3 ELISA kit (EMIGFBP3)                                          ThermoScientific, Australia 
 
Mouse/rat Triiodothyronine ELISA kit (SE120091)                                            Sigma, Australia 
 
Mouse Indian Hedgehog ELISA kit (MBS706033)  MyBioSource Inc., San Diego, USA 
 
Sodium Chloride (NaCl)             Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
 
Sodium Citrate (Na3citrate)        Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
 
Sodium Hydroxide (NaOH)       Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
 
SYBRGreen PCR master mix                               Applied Biosystems, California, USA 
 
OCT                                                                      ProSciTech Pty. Ltd., QLD, Australia 
 
Paraformaldehyde                                                               MP Biomedicals, Ohio, USA 
 
PCR Lysis Reagent                                              Viagen Biotech Inc., Los Angeles, CA 
 
PCR reaction buffer                                        Roche Diagnostics, Mannheim, Germany 
  
Penicillin/ Streptomycin                               Life Technologies Pty. Ltd., VIC, Australia 
 
Phenol                                                        Invitrogen Australia Pty. Ltd., VIC, Australia 
 
Polybrene                                                         Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Potassium hydroxide (KOH)       Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
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Primers and Oligos                                                                  GeneWorks, SA, Australia 
 
Prolong-Gold DAPI (P36931)                                                    ThermoFisher, Australia 
 
Proteinase K                                                      Roche Diagnostics, Mannheim, Germany 
 
Proteinase inhibitor (P8340)                            Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
pUC19/HpaII DNA markers                                                   GeneWorks, SA, Australia 
 
QuantiTect® Reverse Transcription Kit                                     Qiagen, Maryland, USA 
 
Recombinant mouse growth hormone (cat#D-67335) PromoKine, Heidelberg, Germany 
 
Recombinant mouse IGF1 (#791-MG)                                      R&D systems, MN, USA 
 
Recombinant human/mouse IHH (#31705-HH/CF)                 R&D systems, MN, USA 
 
RNaqueous® Micro Kit                                 Ambion, Life technologies, VIC, Australia 
 
RNeasy micro kit                                                                         Qiagen, Maryland, USA 
 
Safranin O                                                              ProSciTech Pty. Ltd., QLD, Australia 
 
SAM-HRP                                                                                              Chemicon, Australia 
 
SDS                                            Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
Sodium Acetate                                                  BDH (Merck) Pty. Ltd., VIC, Australia 
 
Solv21C                                                                      United Bioscience, VIC, Australia 
 
SYBR® Green Master Mix                      Invitrogen Australia Pty. Ltd., VIC, Australia 
 
Taq DNA polymerase                               Roche Diagnostics, Mannheim, Germany 
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Tris-acetate                                                      Roche Diagnostics, Mannheim, Germany 
 
Trypsin/EDTA                                                Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
Trizol Reagent                                         Invitrogen Australia Pty. Ltd., VIC, Australia 
 
3,3′,5-Triiodo-L-thyronine powder (T3, T2877)         Sigma-Aldrich Pty. Ltd., NSW, 
Australia 
 
4C1N                                                             Sigma-Aldrich Pty. Ltd., NSW, Australia 
 
All other reagents used in this study were of analytical reagent grade and were obtained 
from: 
Ajax Finechem Pty. Ltd., Seven Hills, NSW, Australia 
BDH (Merck) Pty. Ltd., VIC, Australia 
Sigma-Aldrich Pty. Ltd., NSW, Australia  
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Appendix B: The number of animals used 












The number of animals per genotype used for radiographic analysis of bone length in normal and affected mice from MPS I, attenuated MPS VII 
(Gustm((L175F)Sly strain), severe MPS VII (Gusmps/mps strain), MPS IIIA and MPS IX P=postnatal day. m=postnatal month. 
 





MPS IIIA strain MPS IX strain 
Normal Affected Normal Affected Normal Affected Normal Affected Normal Affected 
P14 4 4 3 5 6 5 - - - - 
1m 6 16 5 4 13 8 - - - - 
2m 8 9 6 5 18 9 - - - - 
3m 7 8 6 7 7 7 - - - - 
6m 6 11 7 6 9 11 5 8 6 4 
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The number of animals per genotype used for histological analysis of the formation of 
ossification centres in normal and severe MPS VII mice (Gusmps/mps strain). E=embryonic day. 











E12.5  5 6 
E13.5  6 15 
E14.5  8 9 
E15.5  13 13 
E16.5 7 8 
E17.5 5 4 
E18.5 8 5 
P7 4 3 
P8 5 4 
P9 5 4 
P10 15 8 
P11 13 7 
P12 12 10 
P14 15 12 
1m 11 11 
2m 12 7 
6m 9 5 
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The number of animals per genotype used for histomorphometry analysis of the growth 















The number of animals per genotype used for quantitative analysis of area occupied by the 







N MPS VII 
P14 10 10 
1 m 6 8 
2 m 5 5 




P14 14 12 
1m 11 11 
2m 5 7 
6m 9 5 
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Table B5. List of primers used in qRT-PCR. 
 
Cyclophilin A (CycA) was used as a housekeeping gene 
  
Gene Forward primer (5’-3’) Reverse primer (5’-3’) accession # 
Bax CGAGAGGTCTTCTTCCGGGT CACAGGGCCTTGAGCACC NM_007527.3 






Col2a1 AGGTGAACAAGGACCCAGAG AGGATTTCCAGGGGTACCAG NM_031163.3 
CycA AGCATACAGGTCCTGGCATC TTCACCTTCCCAAAGACCAC NM_008907.1 
FasR ATGCACAGAAGGGAAGGAGT CAGGGTGCAGTTTGTTTCCA NM_007987.2 
FasL TGGTTGGAATGGGATTAGGA AAGGCTTTGGTTGGTGAACT NM_010177.4 





















Igfals TCACTCAGTTTGGGCAACAA GGACCACTAGGCTGTTCCAA NM_008340.3 
Igfbp2 GATCTCCACCATGCGCCTT CAGAGACATCTTGCACTGCT NM_008342.3 
































Stat5b AGCAACCACCTCGAGGACTA TACTTCCATCACGCCATCAA 
NM_001113563
.1 
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Appendix C: Publications 
Publication arising from this thesis: 
Jiang Z, Derrick-Roberts ALK, Jackson MR, Rossouw C, Pyragius CE, Xian C, Fletcher 
C and Byers S. Delayed development of ossification centers in the tibia of prenatal and 
early postnatal MPS VII mice, Mol Genet Metab, submitted on 7, March 2018 (accepted 
for publication) 
Published abstract arising from this thesis: 
Jiang Z, Rossouw C, Reichstein C, Macsai CE, Jackson MR, Derrick-Roberts ALK, & 
Byers S. Reduced chondrocyte proliferation and hypertrophy contribute to delayed 
endochondral bone formation in murine Mucopolysaccharidosis VII, Mol Genet Metab 
(2016), vol.117, no.2,pp. S62-S63  
Byers S, Jiang Z, Reichstein C & Derrick-Roberts ALK, Cell cycle progression is 
disrupted in murine MPS VII growth plate chondrocytes, Mol Genet Metab (2017), vol. 
120, Issues 1–2, pp S33. 
Jiang Z, Reichstein C, Derrick-Roberts ALK & Byers S, MPS VII mice display reduced 
circulating IGF1 and disrupted cell cycle progression in the growth plate, Mol Genet 
Metab (2018) , vol. 123 , Issue 2 , pp S71. 
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